BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461. [PMID: 19460966 DOI: 10.1126/science.1171362] [Cited by in Crossref: 2060] [Cited by in F6Publishing: 2070] [Article Influence: 158.5] [Reference Citation Analysis]
Number Citing Articles
1 Mello AM, Ngodup T, Lee Y, Donahue KL, Li J, Rao A, Carpenter ES, Crawford HC, Pasca di Magliano M, Lee KE. Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer. Oncogenesis 2022;11. [DOI: 10.1038/s41389-022-00434-2] [Reference Citation Analysis]
2 Mao W, Zhang L, Rong Y, Kuang T, Wang D, Xu X, Lou W, Li J. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Dig Dis Sci 2022. [PMID: 36098876 DOI: 10.1007/s10620-022-07671-w] [Reference Citation Analysis]
3 Heid I, Trajkovic-Arsic M, Lohöfer F, Kaissis G, Harder FN, Mayer M, Topping GJ, Jungmann F, Crone B, Wildgruber M, Karst U, Liotta L, Algül H, Yen HY, Steiger K, Weichert W, Siveke JT, Makowski MR, Braren RF. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization. Eur J Nucl Med Mol Imaging 2022. [PMID: 36074156 DOI: 10.1007/s00259-022-05930-6] [Reference Citation Analysis]
4 Bazeed AY, Day CM, Garg S. Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies. Cancers 2022;14:4257. [DOI: 10.3390/cancers14174257] [Reference Citation Analysis]
5 Luo J, Cao J, Ma G, Wang X, Sun Y, Zhang C, Shi Z, Zeng Y, Zhang T, Huang P. Collagenase-Loaded H-TiO 2 Nanoparticles Enhance Ultrasound Imaging-Guided Sonodynamic Therapy in a Pancreatic Carcinoma Xenograft Model via Digesting Stromal Barriers. ACS Appl Mater Interfaces. [DOI: 10.1021/acsami.2c08951] [Reference Citation Analysis]
6 Skorupan N, Palestino Dominguez M, Ricci SL, Alewine C. Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:4209. [DOI: 10.3390/cancers14174209] [Reference Citation Analysis]
7 Bian S, Dong H, Zhao L, Li Z, Chen J, Zhu X, Qiu N, Jia X, Song W, Li Z, Zheng S, Wang H, Song P. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. Adv Sci (Weinh) 2022;:e2201931. [PMID: 36026578 DOI: 10.1002/advs.202201931] [Reference Citation Analysis]
8 Carneiro TJ, Pinto J, Serrao EM, Barros AS, Brindle KM, Gil AM. Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model. Front Mol Biosci 2022;9:937865. [DOI: 10.3389/fmolb.2022.937865] [Reference Citation Analysis]
9 Rimal R, Desai P, Daware R, Hosseinnejad A, Prakash J, Lammers T, Singh S. Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. Adv Drug Deliv Rev 2022;189:114504. [PMID: 35998825 DOI: 10.1016/j.addr.2022.114504] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wang D, Li Y, Ge H, Ghadban T, Reeh M, Güngör C. The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC. Cancers 2022;14:3998. [DOI: 10.3390/cancers14163998] [Reference Citation Analysis]
11 Shinkawa T, Ohuchida K, Nakamura M. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer. Cancers 2022;14:3994. [DOI: 10.3390/cancers14163994] [Reference Citation Analysis]
12 Suchors C, Kim J. Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer. Cells 2022;11:2523. [PMID: 36010600 DOI: 10.3390/cells11162523] [Reference Citation Analysis]
13 Smith C, Zheng W, Dong J, Wang Y, Lai J, Liu X, Yin F. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy. World J Gastroenterol 2022; 28(27): 3297-3313 [DOI: 10.3748/wjg.v28.i27.3297] [Reference Citation Analysis]
14 Han S, Fu D, Tushoski GW, Meng L, Herremans KM, Riner AN, Geoge TJ, Huo Z, Hughes SJ. Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma. Theranostics 2022;12:4980-92. [PMID: 35836806 DOI: 10.7150/thno.73222] [Reference Citation Analysis]
15 Liu J, Wang F, Zhang Y, Liu J, Zhao B. ADAR1-Mediated RNA Editing and Its Role in Cancer. Front Cell Dev Biol 2022;10:956649. [DOI: 10.3389/fcell.2022.956649] [Reference Citation Analysis]
16 Masugi Y. The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. Cancers 2022;14:3293. [DOI: 10.3390/cancers14133293] [Reference Citation Analysis]
17 Luo D, Liao S, Li Q, Lin Y, Wei J, Li Y, Liao X. Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). Front Oncol 2022;12:862600. [DOI: 10.3389/fonc.2022.862600] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bhardwaj A, Josse C, Van Daele D, Poulet C, Chavez M, Struman I, Van Steen K. Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. Sci Rep 2022;12:11027. [PMID: 35773268 DOI: 10.1038/s41598-022-14592-1] [Reference Citation Analysis]
19 Casolino R, Corbo V, Beer P, Hwang C, Paiella S, Silvestri V, Ottini L, Biankin AV. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Cancers 2022;14:3239. [DOI: 10.3390/cancers14133239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Barrera LN, Ridley PM, Bermejo-Rodriguez C, Costello E, Perez-Mancera PA. The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis. J Physiol Biochem 2022. [PMID: 35767180 DOI: 10.1007/s13105-022-00899-0] [Reference Citation Analysis]
21 Fuller AM, Eisinger-mathason TSK. Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers. Cancers 2022;14:3132. [DOI: 10.3390/cancers14133132] [Reference Citation Analysis]
22 Obaid G, Bano S, Thomsen H, Callaghan S, Shah N, Swain JWR, Jin W, Ding X, Cameron CG, McFarland SA, Wu J, Vangel M, Stoilova-McPhie S, Zhao J, Mino-Kenudson M, Lin C, Hasan T. Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer. Adv Sci (Weinh) 2022;:e2104594. [PMID: 35748165 DOI: 10.1002/advs.202104594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Duan W, Wang Z, Qian W, Qi D, Ma Q, Wu E. Editorial: The Microenvironment in Pancreatic Cancer and Therapeutic Strategies Targeting Microenvironment. Front Oncol 2022;12:923982. [DOI: 10.3389/fonc.2022.923982] [Reference Citation Analysis]
24 Munir MU. Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue. Cancers (Basel) 2022;14:2904. [PMID: 35740570 DOI: 10.3390/cancers14122904] [Reference Citation Analysis]
25 Garcia-Bermudez J, Badgley MA, Prasad S, Baudrier L, Liu Y, La K, Soula M, Williams RT, Yamaguchi N, Hwang RF, Taylor LJ, de Stanchina E, Rostandy B, Alwaseem H, Molina H, Bar-Sagi D, Birsoy K. Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia. Nat Metab 2022;4:724-38. [PMID: 35726024 DOI: 10.1038/s42255-022-00583-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zhang M, Chen Z, Wang Y, Zhao H, Du Y. The Role of Cancer-Associated Fibroblasts in Ovarian Cancer. Cancers 2022;14:2637. [DOI: 10.3390/cancers14112637] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang Y, Chen X, Wang H, Gordon-Mitchell S, Sahu S, Bhagat TD, Choudhary G, Aluri S, Pradhan K, Sahu P, Carbajal M, Zhang H, Agarwal B, Shastri A, Martell R, Starczynowski D, Steidl U, Maitra A, Verma A. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. J Hematol Oncol 2022;15:70. [PMID: 35606824 DOI: 10.1186/s13045-022-01286-4] [Reference Citation Analysis]
28 Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev 2022;187:114357. [PMID: 35605679 DOI: 10.1016/j.addr.2022.114357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tarannum M, Holtzman K, Dréau D, Mukherjee P, Vivero-Escoto JL. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer. J Control Release 2022:S0168-3659(22)00281-4. [PMID: 35569588 DOI: 10.1016/j.jconrel.2022.05.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Markowski A, Jaromin A, Migdał P, Olczak E, Zygmunt A, Zaremba-Czogalla M, Pawlik K, Gubernator J. Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci 2022;23:5536. [PMID: 35628352 DOI: 10.3390/ijms23105536] [Reference Citation Analysis]
32 Principe DR, Aissa AF, Kumar S, Pham TND, Underwood PW, Nair R, Ke R, Rana B, Trevino JG, Munshi HG, Benevolenskaya EV, Rana A. Calcium channel blockers potentiate gemcitabine chemotherapy  in pancreatic cancer. Proc Natl Acad Sci U S A 2022;119:e2200143119. [PMID: 35476525 DOI: 10.1073/pnas.2200143119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Seki T, Saida Y, Kishimoto S, Lee J, Otowa Y, Yamamoto K, Chandramouli GV, Devasahayam N, Mitchell JB, Krishna MC, Brender JR. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Neoplasia 2022;30:100793. [PMID: 35523073 DOI: 10.1016/j.neo.2022.100793] [Reference Citation Analysis]
34 Fleming Martinez AK, Döppler HR, Bastea LI, Edenfield BH, Liou G, Storz P. Ym1+ macrophages orchestrate fibrosis, lesion growth, and progression during development of murine pancreatic cancer. iScience 2022;25:104327. [DOI: 10.1016/j.isci.2022.104327] [Reference Citation Analysis]
35 Tang Y, Yu Z, Lu X, Fan Q, Huang W. Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines. Adv Sci (Weinh) 2022;9:e2103148. [PMID: 35246962 DOI: 10.1002/advs.202103148] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kong W, Liu Z, Sun M, Liu H, Kong C, Ma J, Wang R, Qian F. Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215718] [Reference Citation Analysis]
37 Ferguson S, Yang KS, Zelga P, Liss AS, Carlson JCT, Del Castillo CF, Weissleder R. Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer. Sci Adv 2022;8:eabm3453. [PMID: 35452280 DOI: 10.1126/sciadv.abm3453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Go Y, Choi WH, Bae WJ, Jung S, Cho C, Lee SA, Park JS, Ahn JM, Kim SW, Lee KJ, Lee D, Yoo J. Modeling Pancreatic Cancer with Patient-Derived Organoids Integrating Cancer-Associated Fibroblasts. Cancers 2022;14:2077. [DOI: 10.3390/cancers14092077] [Reference Citation Analysis]
39 Kerdsirichairat T, Shin EJ. Endoscopic ultrasound guided interventions in the management of pancreatic cancer. World J Gastrointest Endosc 2022; 14(4): 191-204 [DOI: 10.4253/wjge.v14.i4.191] [Reference Citation Analysis]
40 Shi S, Luo Y, Wang M, Lin Z, Song M, Li Z, Peng Z, Feng ST. Tumor fibrosis correlates with the survival of patients with pancreatic adenocarcinoma and is predictable using clinicoradiological features. Eur Radiol 2022. [PMID: 35420301 DOI: 10.1007/s00330-022-08745-z] [Reference Citation Analysis]
41 Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, Kuwata K, Masamune A, Ishihara S, Haga H, Kataoka K, Mii S, Shiraki Y, Ishikawa T, Ohno E, Kawashima H, Hirooka Y, Fujishiro M, Takahashi M, Enomoto A. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. Oncogene 2022. [PMID: 35414659 DOI: 10.1038/s41388-022-02288-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
42 Emori T, Ashida R, Tamura T, Kawaji Y, Hatamaru K, Itonaga M, Yamashita Y, Shimokawa T, Higashino N, Ikoma A, Sonomura T, Kawai M, Kitano M. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.04.005] [Reference Citation Analysis]
43 Peng H, Shen J, Long X, Zhou X, Zhang J, Xu X, Huang T, Xu H, Sun S, Li C, Lei P, Wu H, Zhao J. Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Immunotherapy. Adv Sci (Weinh) 2022;9:e2105240. [PMID: 35128843 DOI: 10.1002/advs.202105240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
44 Russell J, Fanchon L, Alwaseem H, Molina H, O'Donoghue I, Bahr A, de Stanchina E, Pillarsetty N, Humm JL. Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor. Pharmacol Res Perspect 2022;10:e00898. [PMID: 35257504 DOI: 10.1002/prp2.898] [Reference Citation Analysis]
45 Brewer G, Fortier A, Park M, Moraes C. The case for cancer-associated fibroblasts: essential elements in cancer drug discovery? Future Drug Discovery. [DOI: 10.4155/fdd-2021-0004] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Zhu P, Wang L, Xu P, Tan Q, Wang Y, Feng G, Yuan L. GANT61 elevates chemosensitivity to cisplatin through regulating the Hedgehog, AMPK and cAMP pathways in ovarian cancer. Future Med Chem 2022. [PMID: 35322690 DOI: 10.4155/fmc-2021-0310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ikeda-Imafuku M, Wang LL, Rodrigues D, Shaha S, Zhao Z, Mitragotri S. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation. J Control Release 2022:S0168-3659(22)00169-9. [PMID: 35337939 DOI: 10.1016/j.jconrel.2022.03.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer 2022:S2405-8033(22)00055-3. [PMID: 35331673 DOI: 10.1016/j.trecan.2022.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Lv J, Liu Y, Mo S, Zhou Y, Chen F, Cheng F, Li C, Saimi D, Liu M, Zhang H, Tang K, Ma J, Wang Z, Zhu Q, Tong WM, Huang B. Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1-mucin pathway. Nat Cell Biol 2022;24:364-72. [PMID: 35292781 DOI: 10.1038/s41556-022-00857-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Peran I, Vietsch EE, Yan G, Riegel AT, Wellstein A. Distinct Response of Circulating microRNAs to the Treatment of Pancreatic Cancer Xenografts with FGFR and ALK Kinase Inhibitors. Cancers (Basel) 2022;14:1517. [PMID: 35326668 DOI: 10.3390/cancers14061517] [Reference Citation Analysis]
51 Hamada S, Matsumoto R, Masamune A. Pancreatic Stellate Cells and Metabolic Alteration: Physiology and Pathophysiology. Front Physiol 2022;13:865105. [DOI: 10.3389/fphys.2022.865105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Minici C, Testoni S, Della-torre E. B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma. Front Immunol 2022;13:867902. [DOI: 10.3389/fimmu.2022.867902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Correia C, Weiskittel TM, Ung CY, Villasboas Bisneto JC, Billadeau DD, Kaufmann SH, Li H. Uncovering Pharmacological Opportunities for Cancer Stem Cells—A Systems Biology View. Front Cell Dev Biol 2022;10:752326. [DOI: 10.3389/fcell.2022.752326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Zhang X, Zheng S, Hu C, Li G, Lin H, Xia R, Ye Y, He R, Li Z, Lin Q, Chen R, Zhou Q. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene 2022. [PMID: 35264742 DOI: 10.1038/s41388-022-02253-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Blaschuk OW. Potential Therapeutic Applications of N-Cadherin Antagonists and Agonists. Front Cell Dev Biol 2022;10:866200. [DOI: 10.3389/fcell.2022.866200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Falcomatà C, Bärthel S, Widholz SA, Schneeweis C, Montero JJ, Toska A, Mir J, Kaltenbacher T, Heetmeyer J, Swietlik JJ, Cheng JY, Teodorescu B, Reichert O, Schmitt C, Grabichler K, Coluccio A, Boniolo F, Veltkamp C, Zukowska M, Vargas AA, Paik WH, Jesinghaus M, Steiger K, Maresch R, Öllinger R, Ammon T, Baranov O, Robles MS, Rechenberger J, Kuster B, Meissner F, Reichert M, Flossdorf M, Rad R, Schmidt-Supprian M, Schneider G, Saur D. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer 2022;3:318-36. [PMID: 35122074 DOI: 10.1038/s43018-021-00326-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
57 Czekay RP, Cheon DJ, Samarakoon R, Kutz SM, Higgins PJ. Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets. Cancers (Basel) 2022;14:1231. [PMID: 35267539 DOI: 10.3390/cancers14051231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
58 Togni C, Rom E, Burghardt I, Roth P, Rushing EJ, Weller M, Gramatzki D. Prognostic Relevance of Transforming Growth Factor-β Receptor Expression and Signaling in Glioblastoma, Isocitrate Dehydrogenase-Wildtype. J Neuropathol Exp Neurol 2022;81:225-35. [PMID: 35190826 DOI: 10.1093/jnen/nlac007] [Reference Citation Analysis]
59 Blaauboer A, van Koetsveld PM, Mustafa DAM, Dumas J, Dogan F, van Zwienen S, van Eijck CHJ, Hofland LJ. The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. Biomedicines 2022;10:517. [DOI: 10.3390/biomedicines10030517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Jing Y, Liang W, Zhang L, Tang J, Huang Z. The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype. Front Oncol 2022;12:817971. [DOI: 10.3389/fonc.2022.817971] [Reference Citation Analysis]
61 Darvishi B, Eisavand MR, Majidzadeh-a K, Farahmand L. Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance. Br J Cancer. [DOI: 10.1038/s41416-021-01680-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Yang L, Teslaa T, Ng S, Nofal M, Wang L, Lan T, Zeng X, Cowan A, Mcbride M, Lu W, Davidson S, Liang G, Oh TG, Downes M, Evans R, Von Hoff D, Guo JY, Han H, Rabinowitz JD. Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Med 2022;3:119-136.e8. [DOI: 10.1016/j.medj.2021.12.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
63 Mouratidis PXE, Ter Haar G. Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. Cancers (Basel) 2022;14:638. [PMID: 35158903 DOI: 10.3390/cancers14030638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Murray ER, Menezes S, Henry JC, Williams JL, Alba-Castellón L, Baskaran P, Quétier I, Desai A, Marshall JJT, Rosewell I, Tatari M, Rajeeve V, Khan F, Wang J, Kotantaki P, Tyler EJ, Singh N, Reader CS, Carter EP, Hodivala-Dilke K, Grose RP, Kocher HM, Gavara N, Pearce O, Cutillas P, Marshall JF, Cameron AJM. Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Cell Rep 2022;38:110227. [PMID: 35081338 DOI: 10.1016/j.celrep.2021.110227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
65 Roalsø MTT, Hald ØH, Alexeeva M, Søreide K. Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:546. [DOI: 10.3390/cancers14030546] [Reference Citation Analysis]
66 Huang S, Zhang X, Luo K, Jiang L, Jiang J, Li R. Oxysterol-Binding Protein 2 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Epithelial-Mesenchymal Transition. Front Oncol 2022;11:762233. [DOI: 10.3389/fonc.2021.762233] [Reference Citation Analysis]
67 Kotulova J, Lonova K, Kubickova A, Vrbkova J, Kourilova P, Hajduch M, Dzubak P. 2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines. Int J Mol Med 2022;49:31. [PMID: 35039871 DOI: 10.3892/ijmm.2022.5086] [Reference Citation Analysis]
68 Hamada S, Matsumoto R, Masamune A. HIF-1 and NRF2; Key Molecules for Malignant Phenotypes of Pancreatic Cancer. Cancers 2022;14:411. [DOI: 10.3390/cancers14020411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
69 Chiavarina B, Ronca R, Otaka Y, Sutton RB, Rezzola S, Yokobori T, Chiodelli P, Souche R, Pourquier D, Maraver A, Faa G, Khellaf L, Turtoi E, Oyama T, Gofflot S, Bellahcène A, Detry O, Delvenne P, Castronovo V, Nishiyama M, Turtoi A. Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. Oncogene 2022. [PMID: 35031773 DOI: 10.1038/s41388-021-02171-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Kubo K, Itto-Nakama K, Ohnuki S, Yashiroda Y, Li SC, Kimura H, Kawamura Y, Shimamoto Y, Tominaga KI, Yamanaka D, Adachi Y, Takashima S, Noda Y, Boone C, Ohya Y. Jerveratrum-Type Steroidal Alkaloids Inhibit β-1,6-Glucan Biosynthesis in Fungal Cell Walls. Microbiol Spectr 2022;:e0087321. [PMID: 35019680 DOI: 10.1128/spectrum.00873-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Strittmatter N, Richards FM, Race AM, Ling S, Sutton D, Nilsson A, Wallez Y, Barnes J, Maglennon G, Gopinathan A, Brais R, Wong E, Serra MP, Atkinson J, Smith A, Wilson J, Hamm G, Johnson TI, Dunlop CR, Kaistha BP, Bunch J, Sansom OJ, Takats Z, Andrén PE, Lau A, Barry ST, Goodwin RJA, Jodrell DI. Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Anal Chem . [DOI: 10.1021/acs.analchem.1c04579] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Quatannens D, Verhoeven Y, Van Dam P, Lardon F, Prenen H, Roeyen G, Peeters M, Smits ELJ, Van Audenaerde J. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. Pharmacol Ther 2022;236:108107. [PMID: 34999181 DOI: 10.1016/j.pharmthera.2022.108107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
73 Yang Y, Shi XQ, Chen G, Zhou XN, Qian LX. Contrast-enhanced ultrasound for evaluating response to pulsed-wave high-intensity focused ultrasound therapy in advanced pancreatic cancer. Clin Hemorheol Microcirc 2022. [PMID: 35001881 DOI: 10.3233/CH-211342] [Reference Citation Analysis]
74 Suzuki J, Tsuboi M, Ishii G. Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer. Expert Rev Anticancer Ther 2022;:1-14. [PMID: 34904919 DOI: 10.1080/14737140.2022.2019018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Lopez S, Hallali N, Lalatonne Y, Hillion A, Antunes JC, Serhan N, Clerc P, Fourmy D, Motte L, Carrey J, Gigoux V. Magneto-mechanical destruction of cancer-associated fibroblasts using ultra-small iron oxide nanoparticles and low frequency rotating magnetic fields. Nanoscale Adv 2022;4:421-36. [DOI: 10.1039/d1na00474c] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
76 Xu X, Wu Y, Qian X, Wang Y, Wang J, Li J, Li Y, Zhang Z. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy. Adv Healthc Mater 2022;11:e2101428. [PMID: 34706400 DOI: 10.1002/adhm.202101428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Wu W, Yang H, Wang Z, Zhang Z, Lu X, Yang W, Xu X, Jiang Y, Li Y, Fan X, Shao Q. A Noncanonical Hedgehog Signaling Exerts a Tumor-Promoting Effect on Pancreatic Cancer Cells Via Induction of Osteopontin Expression. Cancer Biother Radiopharm 2021. [PMID: 34978897 DOI: 10.1089/cbr.2021.0317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Pratt HG, Steinberger KJ, Mihalik NE, Ott S, Whalley T, Szomolay B, Boone BA, Eubank TD. Macrophage and Neutrophil Interactions in the Pancreatic Tumor Microenvironment Drive the Pathogenesis of Pancreatic Cancer. Cancers (Basel) 2021;14:194. [PMID: 35008355 DOI: 10.3390/cancers14010194] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
79 Hyun J, Kim HW. Leveraging cellular mechano-responsiveness for cancer therapy. Trends Mol Med 2021:S1471-4914(21)00317-8. [PMID: 34973934 DOI: 10.1016/j.molmed.2021.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Malinova A, Veghini L, Real FX, Corbo V. Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Front Cell Dev Biol 2021;9:795251. [PMID: 34926472 DOI: 10.3389/fcell.2021.795251] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
81 Maneshi P, Mason J, Dongre M, Öhlund D. Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits. Front Cell Dev Biol 2021;9:787485. [PMID: 34901028 DOI: 10.3389/fcell.2021.787485] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
82 Vaish U, Jain T, Are AC, Dudeja V. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Int J Mol Sci 2021;22:13408. [PMID: 34948209 DOI: 10.3390/ijms222413408] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
83 Narayanan S, Vicent S, Ponz-sarvisé M. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem? Front Cell Dev Biol 2021;9:787249. [DOI: 10.3389/fcell.2021.787249] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
84 Rajagopal MU, Bansal S, Kaur P, Jain SK, Altadil T, Hinzman CP, Li Y, Moulton J, Singh B, Bansal S, Chauthe SK, Singh R, Banerjee PP, Mapstone M, Fiandaca MS, Federoff HJ, Unger K, Smith JP, Cheema AK. TGFβ Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFβ Induced EMT in PDAC. Cancers (Basel) 2021;13:6204. [PMID: 34944824 DOI: 10.3390/cancers13246204] [Reference Citation Analysis]
85 Opitz FV, Haeberle L, Daum A, Esposito I. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. Cancers 2021;13:6188. [DOI: 10.3390/cancers13246188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
86 Carvalho TMA, Di Molfetta D, Greco MR, Koltai T, Alfarouk KO, Reshkin SJ, Cardone RA. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. Cancers (Basel) 2021;13:6135. [PMID: 34885243 DOI: 10.3390/cancers13236135] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
87 Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 McDonald OG. The biology of pancreatic cancer morphology. Pathology 2021:S0031-3025(21)00522-5. [PMID: 34872751 DOI: 10.1016/j.pathol.2021.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Yu W, Sharma S, Rao E, Rowat AC, Gimzewski JK, Han D, Rao J. Cancer Cell Mechanobiology: A New Frontier for Cancer Research. Journal of the National Cancer Center 2021. [DOI: 10.1016/j.jncc.2021.11.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Yu KH, Ozer M, Cockrum P, Surinach A, Wang S, Chu BC. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med 2021;10:8934-43. [PMID: 34811961 DOI: 10.1002/cam4.4415] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
91 Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbro E, Parrino A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M. Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opin Ther Targets 2021;:1-19. [PMID: 34806517 DOI: 10.1080/14728222.2021.2010044] [Reference Citation Analysis]
92 Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E. Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery? J Gastrointest Oncol 2021;12:2450-60. [PMID: 34790406 DOI: 10.21037/jgo-2020-slapc-04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Hwang HH, Jeong HJ, Yun S, Byun Y, Okano T, Kim SW, Lee DY. Anticancer Effect of Heparin-Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer. Cancers (Basel) 2021;13:5775. [PMID: 34830928 DOI: 10.3390/cancers13225775] [Reference Citation Analysis]
94 Huang S, Huang X, Yan H. Peptide dendrimers as potentiators of conventional chemotherapy in the treatment of pancreatic cancer in a mouse model. Eur J Pharm Biopharm 2021:S0939-6411(21)00278-2. [PMID: 34801706 DOI: 10.1016/j.ejpb.2021.11.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Miquel M, Zhang S, Pilarsky C. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:748631. [PMID: 34778259 DOI: 10.3389/fcell.2021.748631] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
96 Loh JJ, Ma S. The Role of Cancer-Associated Fibroblast as a Dynamic Player in Mediating Cancer Stemness in the Tumor Microenvironment. Front Cell Dev Biol 2021;9:727640. [PMID: 34760886 DOI: 10.3389/fcell.2021.727640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
97 Seebacher NA, Krchniakova M, Stacy AE, Skoda J, Jansson PJ. Tumour Microenvironment Stress Promotes the Development of Drug Resistance. Antioxidants (Basel) 2021;10:1801. [PMID: 34829672 DOI: 10.3390/antiox10111801] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
98 Ho WW, Gomes-Santos IL, Aoki S, Datta M, Kawaguchi K, Talele NP, Roberge S, Ren J, Liu H, Chen IX, Andersson P, Chatterjee S, Kumar AS, Amoozgar Z, Zhang Q, Huang P, Ng MR, Chauhan VP, Xu L, Duda DG, Clark JW, Pittet MJ, Fukumura D, Jain RK. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc Natl Acad Sci U S A 2021;118:e2105323118. [PMID: 34725151 DOI: 10.1073/pnas.2105323118] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
99 Palamaris K, Felekouras E, Sakellariou S. Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. Cancers (Basel) 2021;13:5532. [PMID: 34771695 DOI: 10.3390/cancers13215532] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
100 Cho K, Ro SW, Lee HW, Moon H, Han S, Kim HR, Ahn SH, Park JY, Kim DY. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. Hepatology 2021;74:2605-21. [PMID: 34101869 DOI: 10.1002/hep.32000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
101 Pang H, Zhou Y, Wang J, Wu H, Cui C, Xiao Z. SKA3 overexpression predicts poor outcomes in skin cutaneous melanoma patients. Transl Oncol 2021;15:101253. [PMID: 34737118 DOI: 10.1016/j.tranon.2021.101253] [Reference Citation Analysis]
102 Honkala A, Malhotra SV, Kummar S, Junttila MR. Harnessing the predictive power of preclinical models for oncology drug development. Nat Rev Drug Discov 2021. [PMID: 34702990 DOI: 10.1038/s41573-021-00301-6] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
103 Perez VM, Kearney JF, Yeh JJ. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. Front Oncol 2021;11:751311. [PMID: 34692532 DOI: 10.3389/fonc.2021.751311] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
104 Wang M, Li XZ, Zhang MX, Ye QY, Chen YX, Chang X. Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation. Front Oncol 2021;11:738534. [PMID: 34692516 DOI: 10.3389/fonc.2021.738534] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
105 Lodestijn SC, Miedema DM, Lenos KJ, Nijman LE, Belt SC, El Makrini K, Lecca MC, Waasdorp C, van den Bosch T, Bijlsma MF, Vermeulen L. Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer. Cell Rep 2021;37:109852. [PMID: 34686335 DOI: 10.1016/j.celrep.2021.109852] [Reference Citation Analysis]
106 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Manoukian P, Bijlsma M, van Laarhoven H. The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth. Front Cell Dev Biol 2021;9:743907. [PMID: 34646829 DOI: 10.3389/fcell.2021.743907] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
108 Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua J, Liu J, Wang W, Shi S, Yu X, Liang C. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Int J Mol Sci 2021;22:10944. [PMID: 34681603 DOI: 10.3390/ijms222010944] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
109 Zhuang L, Yao Y, Peng L, Cui F, Chen C, Zhang Y, Sun L, Yu Q, Lin K. Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway. Dig Dis Sci 2021. [PMID: 34623580 DOI: 10.1007/s10620-021-07262-1] [Reference Citation Analysis]
110 Schlick K, Kiem D, Greil R. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Biomolecules 2021;11:1469. [PMID: 34680101 DOI: 10.3390/biom11101469] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Weitz JR, Tiriac H, Hurtado de Mendoza T, Wascher A, Lowy AM. Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond. Cancers (Basel) 2021;13:4991. [PMID: 34638476 DOI: 10.3390/cancers13194991] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
112 Watt DM, Morton JP. Heterogeneity in Pancreatic Cancer Fibroblasts-TGFβ as a Master Regulator? Cancers (Basel) 2021;13:4984. [PMID: 34638468 DOI: 10.3390/cancers13194984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Schlick K, Kiem D, Huemer F, Neureiter D, Weiss L, Greil R. Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Technol Cancer Res Treat 2021;20:15330338211042139. [PMID: 34595977 DOI: 10.1177/15330338211042139] [Reference Citation Analysis]
114 Herting CJ, Karpovsky I, Lesinski GB. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Cancer Metastasis Rev 2021;40:675-89. [PMID: 34591240 DOI: 10.1007/s10555-021-09988-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Barbagallo M, Ciprani D, Rimassa L, Cortese N, Comito T, Spaggiari P, Marchesi F, Zerbi A. The Immune Landscape in a Long-Term Survival Pancreatic Adenocarcinoma Patient Highly Responsive to a Multidisciplinary Approach With Chemo-Radio Treatments. Pancreas 2021;50:e76-8. [PMID: 34860821 DOI: 10.1097/MPA.0000000000001907] [Reference Citation Analysis]
116 Tanaka Y, Hamada S, Matsumoto R, Taguchi K, Yamamoto M, Masamune A. Nrf2 expression in pancreatic stellate cells promotes progression of cancer. Am J Physiol Gastrointest Liver Physiol 2021;321:G378-88. [PMID: 34405729 DOI: 10.1152/ajpgi.00120.2021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
117 Murphy KJ, Reed DA, Vennin C, Conway JRW, Nobis M, Yin JX, Chambers CR, Pereira BA, Lee V, Filipe EC, Trpceski M, Ritchie S, Lucas MC, Warren SC, Skhinas JN, Magenau A, Metcalf XL, Stoehr J, Major G, Parkin A, Bidanel R, Lyons RJ, Zaratzian A, Tayao M, Da Silva A, Abdulkhalek L, Gill AJ, Johns AL, Biankin AV, Samra J, Grimmond SM, Chou A, Goetz JG, Samuel MS, Lyons JG, Burgess A, Caldon CE, Horvath LG, Daly RJ, Gadegaard N, Wang Y, Sansom OJ, Morton JP, Cox TR, Pajic M, Herrmann D, Timpson P; Australian Pancreatic Genome Initiative (APGI)., Australian Pancreatic Cancer Matrix Atlas (APMA). Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Sci Adv 2021;7:eabh0363. [PMID: 34586840 DOI: 10.1126/sciadv.abh0363] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
118 Pijnappel EN, Wassenaar NPM, Gurney-Champion OJ, Klaassen R, van der Lee K, Pleunis-van Empel MCH, Richel DJ, Legdeur MC, Nederveen AJ, van Laarhoven HWM, Wilmink JW. Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancers (Basel) 2021;13:4869. [PMID: 34638351 DOI: 10.3390/cancers13194869] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 KalantarMotamedi Y, Choi RJ, Koh SB, Bramhall JL, Fan TP, Bender A. Prediction and identification of synergistic compound combinations against pancreatic cancer cells. iScience 2021;24:103080. [PMID: 34585118 DOI: 10.1016/j.isci.2021.103080] [Reference Citation Analysis]
120 Lu T, Prakash J. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer. Int J Nanomedicine 2021;16:6313-28. [PMID: 34552327 DOI: 10.2147/IJN.S279192] [Reference Citation Analysis]
121 Chai JY, Sugumar V, Alshanon AF, Wong WF, Fung SY, Looi CY. Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches. Cancers (Basel) 2021;13:4746. [PMID: 34638233 DOI: 10.3390/cancers13194746] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Asif PJ, Longobardi C, Hahne M, Medema JP. The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis. Cancers (Basel) 2021;13:4720. [PMID: 34572947 DOI: 10.3390/cancers13184720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
123 Hollinshead KER, Parker SJ, Eapen VV, Encarnacion-Rosado J, Sohn A, Oncu T, Cammer M, Mancias JD, Kimmelman AC. Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer. Cell Rep 2020;33:108231. [PMID: 33027658 DOI: 10.1016/j.celrep.2020.108231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
124 Ware MB, El-Rayes BF, Lesinski GB. Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. J Immunother Cancer 2020;8:e001100. [PMID: 32843336 DOI: 10.1136/jitc-2020-001100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kearney JF, Adsay V, Yeh JJ. Pathology and Molecular Characteristics of Pancreatic Cancer. Surg Oncol Clin N Am 2021;30:609-19. [PMID: 34511185 DOI: 10.1016/j.soc.2021.06.003] [Reference Citation Analysis]
126 Cho IK, Kim H, Lee JC, Lee J, Kim J, Ahn S, Park H, Hwang JH. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Gut Liver 2020;14:521-8. [PMID: 31615191 DOI: 10.5009/gnl19180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Chai JY, Sugumar V, Alshawsh MA, Wong WF, Arya A, Chong PP, Looi CY. The Role of Smoothened-Dependent and -Independent Hedgehog Signaling Pathway in Tumorigenesis. Biomedicines 2021;9:1188. [PMID: 34572373 DOI: 10.3390/biomedicines9091188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
128 Kahn BM, Lucas A, Alur RG, Wengyn MD, Schwartz GW, Li J, Sun K, Maurer HC, Olive KP, Faryabi RB, Stanger BZ. The vascular landscape of human cancer. J Clin Invest 2021;131:136655. [PMID: 33258803 DOI: 10.1172/JCI136655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
129 Reese M, Dhayat SA. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. J Hematol Oncol 2021;14:141. [PMID: 34496946 DOI: 10.1186/s13045-021-01149-4] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
130 Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol 2021. [PMID: 34489603 DOI: 10.1038/s41571-021-00546-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 51] [Article Influence: 1.0] [Reference Citation Analysis]
131 Ferrara B, Pignatelli C, Cossutta M, Citro A, Courty J, Piemonti L. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers (Basel) 2021;13:4442. [PMID: 34503252 DOI: 10.3390/cancers13174442] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
132 Tan ML, Ling L, Fischbach C. Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro. Adv Drug Deliv Rev 2021;176:113852. [PMID: 34197895 DOI: 10.1016/j.addr.2021.113852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
133 Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, Ricci C, Scambia G, Fagotti A. Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin Cancer Biol 2021;77:144-66. [PMID: 34464704 DOI: 10.1016/j.semcancer.2021.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Karimnia V, Slack FJ, Celli JP. Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4354. [PMID: 34503165 DOI: 10.3390/cancers13174354] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
135 Ko YC, Choi HS, Liu R, Lee DS. Physalin A, 13,14-Seco-16, 24-Cyclo-Steroid, Inhibits Stemness of Breast Cancer Cells by Regulation of Hedgehog Signaling Pathway and Yes-Associated Protein 1 (YAP1). Int J Mol Sci 2021;22:8718. [PMID: 34445421 DOI: 10.3390/ijms22168718] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
136 Duan N, Li J, Song S, Wang F, Yang Y, Nie D, Wang C, Sheng Y, Tao Y, Gao J, Xu C, Wei Y, Gan Y. Enzyme‐Activated Prodrug‐Based Smart Liposomes Specifically Enhance Tumor Hemoperfusion with Efficient Drug Delivery to Pancreatic Cancer Cells and Stellate Cells. Adv Funct Materials 2021;31:2100605. [DOI: 10.1002/adfm.202100605] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
137 Liang Y, Yang L, Xie J. The Role of the Hedgehog Pathway in Chemoresistance of Gastrointestinal Cancers. Cells 2021;10:2030. [PMID: 34440799 DOI: 10.3390/cells10082030] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
138 Havnar C, Lau S, Hung J, Eastham-Anderson J, Espiritu C, Rangell L, Koeppen H, Ziai J, Foreman O. Characterization of Tumor-immune Microenvironment by High-throughput Image Analysis of CD8 Immunohistochemistry Combined With Modified Masson's Trichrome. J Histochem Cytochem 2021;:221554211034935. [PMID: 34353148 DOI: 10.1369/00221554211034935] [Reference Citation Analysis]
139 Chandra Jena B, Sarkar S, Rout L, Mandal M. The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance. Cancer Lett 2021;520:222-32. [PMID: 34363903 DOI: 10.1016/j.canlet.2021.08.002] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
140 Wu K, Huynh KQ, Lu I, Moustakim M, Miao H, Yu C, Haeusgen MJ, Hopkins BD, Huang L, Zheng N, Sanchez R, DeVita RJ, Pan ZQ. Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential. Proc Natl Acad Sci U S A 2021;118:e2007328118. [PMID: 33602808 DOI: 10.1073/pnas.2007328118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Ager CR, Boda A, Rajapakshe K, Lea ST, Di Francesco ME, Jayaprakash P, Slay RB, Morrow B, Prasad R, Dean MA, Duffy CR, Coarfa C, Jones P, Curran MA. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. J Immunother Cancer 2021;9:e003246. [PMID: 34341132 DOI: 10.1136/jitc-2021-003246] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
142 Tang LJW, Zaseela A, Toh CCM, Adine C, Aydar AO, Iyer NG, Fong ELS. Engineering stromal heterogeneity in cancer. Adv Drug Deliv Rev 2021;175:113817. [PMID: 34087326 DOI: 10.1016/j.addr.2021.05.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Delaney LJ, Eisenbrey JR, Brown D, Brody JR, Jimbo M, Oeffinger BE, Stanczak M, Forsberg F, Liu JB, Wheatley MA. Gemcitabine-loaded microbubble system for ultrasound imaging and therapy. Acta Biomater 2021;130:385-94. [PMID: 34082100 DOI: 10.1016/j.actbio.2021.05.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
144 Wang FT, Li XP, Pan MS, Hassan M, Sun W, Fan YZ. Identification of the prognostic value of elevated ANGPTL4 expression in gallbladder cancer-associated fibroblasts. Cancer Med 2021;10:6035-47. [PMID: 34331381 DOI: 10.1002/cam4.4150] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
145 Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, Harlé A. Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals (Basel) 2021;14:740. [PMID: 34451837 DOI: 10.3390/ph14080740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Oyama Y, Onishi H, Koga S, Murahashi M, Ichimiya S, Nakayama K, Fujimura A, Kawamoto M, Imaizumi A, Umebayashi M, Ohuchida K, Morisaki T, Nakamura M. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. J Immunother 2020;43:121-33. [PMID: 31834207 DOI: 10.1097/CJI.0000000000000305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
147 Ebelt ND, Zamloot V, Zuniga E, Passi KB, Sobocinski LJ, Young CA, Blazar BR, Manuel ER. Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. Cancers (Basel) 2021;13:3565. [PMID: 34298778 DOI: 10.3390/cancers13143565] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
148 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
149 Geng X, Chen H, Zhao L, Hu J, Yang W, Li G, Cheng C, Zhao Z, Zhang T, Li L, Sun B. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Front Cell Dev Biol 2021;9:655152. [PMID: 34336821 DOI: 10.3389/fcell.2021.655152] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
150 Guo JA, Hoffman HI, Weekes CD, Zheng L, Ting DT, Hwang WL. Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Clin Cancer Res 2021;27:3825-33. [PMID: 33653818 DOI: 10.1158/1078-0432.CCR-20-4712] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
151 Lan H, Zhang W, Jin K, Liu Y, Wang Z. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Deliv 2020;27:1248-62. [PMID: 32865029 DOI: 10.1080/10717544.2020.1809559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
152 Maia A, Wiemann S. Cancer-Associated Fibroblasts: Implications for Cancer Therapy. Cancers (Basel) 2021;13:3526. [PMID: 34298736 DOI: 10.3390/cancers13143526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
153 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
154 Hutton C, Heider F, Blanco-Gomez A, Banyard A, Kononov A, Zhang X, Karim S, Paulus-Hock V, Watt D, Steele N, Kemp S, Hogg EKJ, Kelly J, Jackstadt RF, Lopes F, Menotti M, Chisholm L, Lamarca A, Valle J, Sansom OJ, Springer C, Malliri A, Marais R, Pasca di Magliano M, Zelenay S, Morton JP, Jørgensen C. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell 2021:S1535-6108(21)00339-1. [PMID: 34297917 DOI: 10.1016/j.ccell.2021.06.017] [Cited by in F6Publishing: 37] [Reference Citation Analysis]
155 Murphy KJ, Chambers CR, Herrmann D, Timpson P, Pereira BA. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Cancers (Basel) 2021;13:3481. [PMID: 34298706 DOI: 10.3390/cancers13143481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
156 Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C. Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy? Cancers (Basel) 2021;13:3466. [PMID: 34298680 DOI: 10.3390/cancers13143466] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
157 Le DT, Huynh TR, Burt B, Van Buren G, Abeynaike SA, Zalfa C, Nikzad R, Kheradmand F, Tyner JJ, Paust S. Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft. JCI Insight 2021;6:140116. [PMID: 34081628 DOI: 10.1172/jci.insight.140116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Mouratidis PXE, Costa M, Rivens I, Repasky EE, Ter Haar G. Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. J R Soc Interface 2021;18:20210266. [PMID: 34229458 DOI: 10.1098/rsif.2021.0266] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
159 Heinrich MA, Mostafa AMRH, Morton JP, Hawinkels LJAC, Prakash J. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Deliv Rev 2021;174:265-93. [PMID: 33895214 DOI: 10.1016/j.addr.2021.04.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
160 Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I. Emerging Treatment Strategies in Pancreatic Cancer. Pancreas 2021;50:773-87. [PMID: 34398070 DOI: 10.1097/MPA.0000000000001845] [Reference Citation Analysis]
161 Pfeifer E, Burchell JM, Dazzi F, Sarker D, Beatson R. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts. Cells 2021;10:1653. [PMID: 34359823 DOI: 10.3390/cells10071653] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
162 Lodestijn SC, van Neerven SM, Vermeulen L, Bijlsma MF. Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. Cancers (Basel) 2021;13:3295. [PMID: 34209288 DOI: 10.3390/cancers13133295] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma? Cancers (Basel) 2021;13:3248. [PMID: 34209646 DOI: 10.3390/cancers13133248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
164 Ou W, Xu W, Liu F, Guo Y, Huang Z, Feng T, Liu CY, Du P. Increased expression of yes-associated protein/YAP and transcriptional coactivator with PDZ-binding motif/TAZ activates intestinal fibroblasts to promote intestinal obstruction in Crohn's disease. EBioMedicine 2021;69:103452. [PMID: 34186485 DOI: 10.1016/j.ebiom.2021.103452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Adjuto-Saccone M, Soubeyran P, Garcia J, Audebert S, Camoin L, Rubis M, Roques J, Binétruy B, Iovanna JL, Tournaire R. TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. Cell Death Dis 2021;12:649. [PMID: 34172716 DOI: 10.1038/s41419-021-03920-4] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
166 Mahajan UM, Li Q, Alnatsha A, Maas J, Orth M, Maier SH, Peterhansl J, Regel I, Sendler M, Wagh PR, Mishra N, Xue Y, Allawadhi P, Beyer G, Kühn JP, Marshall T, Appel B, Lämmerhirt F, Belka C, Müller S, Weiss FU, Lauber K, Lerch MM, Mayerle J. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. Gastroenterology 2021;161:996-1010.e1. [PMID: 34097885 DOI: 10.1053/j.gastro.2021.05.055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
167 Xiao Y, Qin T, Sun L, Qian W, Li J, Duan W, Lei J, Wang Z, Ma J, Li X, Ma Q, Xu Q. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Cell Transplant. 2020;29:963689720929987. [PMID: 32463297 DOI: 10.1177/0963689720929987] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
168 Pradhan RN, Krishnamurty AT, Fletcher AL, Turley SJ, Müller S. A bird's eye view of fibroblast heterogeneity: A pan-disease, pan-cancer perspective. Immunol Rev 2021;302:299-320. [PMID: 34164824 DOI: 10.1111/imr.12990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Fernández-Nogueira P, Fuster G, Gutierrez-Uzquiza Á, Gascón P, Carbó N, Bragado P. Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis. Cancers (Basel) 2021;13:3146. [PMID: 34201840 DOI: 10.3390/cancers13133146] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
170 Jaynes JM, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, Li D, Calvo R, Dashnyam M, Singh A, Guerin T, White J, Ravichandran S, Kumar P, Talsania K, Chen V, Ghebremedhin A, Karanam B, Bin Salam A, Amin R, Odzorig T, Aiken T, Nguyen V, Bian Y, Zarif JC, de Groot AE, Mehta M, Fan L, Hu X, Simeonov A, Pate N, Abu-Asab M, Ferrer M, Southall N, Ock CY, Zhao Y, Lopez H, Kozlov S, de Val N, Yates CC, Baljinnyam B, Marugan J, Rudloff U. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med 2020;12:eaax6337. [PMID: 32051227 DOI: 10.1126/scitranslmed.aax6337] [Cited by in Crossref: 50] [Cited by in F6Publishing: 80] [Article Influence: 50.0] [Reference Citation Analysis]
171 Hussain Z, Nigri J, Tomasini R. The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:3040. [PMID: 34207163 DOI: 10.3390/cancers13123040] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
172 Ahmad RS, Eubank TD, Lukomski S, Boone BA. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. Biomolecules 2021;11:901. [PMID: 34204306 DOI: 10.3390/biom11060901] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
173 Martin JD, Miyazaki T, Cabral H. Remodeling tumor microenvironment with nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1730. [PMID: 34124849 DOI: 10.1002/wnan.1730] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
174 Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev 2021;35:940-62. [PMID: 34117095 DOI: 10.1101/gad.348523.121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Ding H, Sun J, Song Y, Xin W, Zhu J, Zhong L, Chen Y, Zhang Y, Tong Y, Fang L. Long Distance From Microvessel to Cancer Cell Predicts Poor Prognosis in Non-Small Cell Lung Cancer Patients. Front Oncol 2021;11:632352. [PMID: 34178623 DOI: 10.3389/fonc.2021.632352] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
176 Hao X, Ren Y, Feng M, Wang Q, Wang Y. Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more. Biomed Pharmacother 2021;141:111798. [PMID: 34120068 DOI: 10.1016/j.biopha.2021.111798] [Reference Citation Analysis]
177 Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Deng S, Zhou H. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther 2021;6:218. [PMID: 34108441 DOI: 10.1038/s41392-021-00641-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 41] [Article Influence: 1.0] [Reference Citation Analysis]
178 Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol 2021;14:91. [PMID: 34108022 DOI: 10.1186/s13045-021-01105-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
179 Maddalena M, Mallel G, Nataraj NB, Shreberk-Shaked M, Hassin O, Mukherjee S, Arandkar S, Rotkopf R, Kapsack A, Lambiase G, Pellegrino B, Ben-Isaac E, Golani O, Addadi Y, Hajaj E, Eilam R, Straussman R, Yarden Y, Lotem M, Oren M. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc Natl Acad Sci U S A 2021;118:e2025631118. [PMID: 34088837 DOI: 10.1073/pnas.2025631118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
180 Sun H, Zhang D, Huang C, Guo Y, Yang Z, Yao N, Dong X, Cheng R, Zhao N, Meng J, Sun B, Hao J. Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer. Cancer Biol Med 2021:j. [PMID: 34086429 DOI: 10.20892/j.issn.2095-3941.2021.0158] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
181 Grapa CM, Mocan L, Crisan D, Florea M, Mocan T. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. Materials (Basel) 2021;14:3083. [PMID: 34199998 DOI: 10.3390/ma14113083] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
182 Dzobo K, Dandara C. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. OMICS 2020;24:314-39. [PMID: 32496970 DOI: 10.1089/omi.2020.0023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
183 Desbois M, Wang Y. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. Immunol Rev 2021;302:241-58. [PMID: 34075584 DOI: 10.1111/imr.12982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
184 Shimazaki R, Takano S, Satoh M, Takada M, Miyahara Y, Sasaki K, Yoshitomi H, Kagawa S, Furukawa K, Takayashiki T, Kuboki S, Sogawa K, Motohashi S, Nomura F, Miyazaki M, Ohtsuka M. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cell Oncol (Dordr) 2021;44:937-50. [PMID: 34075561 DOI: 10.1007/s13402-021-00614-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Wang J, Wu Q, Wang Y, Xiang L, Feng J, Zhou Z, Fu Q, Zhang L. Collagenase-loaded pH-sensitive nanocarriers efficiently remodeled tumor stroma matrixes and improved the enrichment of nanomedicines. Nanoscale 2021;13:9402-14. [PMID: 34002757 DOI: 10.1039/d1nr00950h] [Reference Citation Analysis]
186 Hou Y, Wang X, Wang J, Sun X, Liu X, Hu H, Fan W, Zhang X, Wu D. Cyclin B1 acts as a tumor microenvironment-related cancer promoter and prognostic biomarker in hepatocellular carcinoma. J Int Med Res 2021;49:3000605211016265. [PMID: 34044639 DOI: 10.1177/03000605211016265] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Johnson TI, Minteer CJ, Kottmann D, Dunlop CR, Fernández SBQ, Carnevalli LS, Wallez Y, Lau A, Richards FM, Jodrell DI. Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach. EBioMedicine 2021;68:103396. [PMID: 34049239 DOI: 10.1016/j.ebiom.2021.103396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Raskov H, Orhan A, Gaggar S, Gögenur I. Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy. Front Oncol 2021;11:668731. [PMID: 34094963 DOI: 10.3389/fonc.2021.668731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
189 Burton KM, Johnson KM, Krueger EW, Razidlo GL, McNiven MA. Distinct forms of the actin cross-linking protein α-actinin support macropinosome internalization and trafficking. Mol Biol Cell 2021;32:1393-407. [PMID: 34010028 DOI: 10.1091/mbc.E20-12-0755] [Reference Citation Analysis]
190 Mhaidly R, Mechta-Grigoriou F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev 2021;302:259-72. [PMID: 34013544 DOI: 10.1111/imr.12978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
191 Kokkinos J, Jensen A, Sharbeen G, McCarroll JA, Goldstein D, Haghighi KS, Phillips PA. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? Cancers (Basel) 2021;13:2427. [PMID: 34067833 DOI: 10.3390/cancers13102427] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
192 Tabdanov ED, Rodríguez-Merced NJ, Cartagena-Rivera AX, Puram VV, Callaway MK, Ensminger EA, Pomeroy EJ, Yamamoto K, Lahr WS, Webber BR, Moriarity BS, Zhovmer AS, Provenzano PP. Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments. Nat Commun 2021;12:2815. [PMID: 33990566 DOI: 10.1038/s41467-021-22985-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
193 Polani F, Grierson PM, Lim KH. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World J Gastroenterol 2021; 27(18): 2105-2121 [PMID: 34025067 DOI: 10.3748/wjg.v27.i18.2105] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
194 Yunna C, Mengru H, Fengling W, Lei W, Weidong C. Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor. Eur J Pharm Biopharm 2021;165:75-83. [PMID: 33991610 DOI: 10.1016/j.ejpb.2021.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Kothari A, Flick MJ. Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2021;22:5138. [PMID: 34066284 DOI: 10.3390/ijms22105138] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
196 Krishnamoorthy M, Gerhardt L, Maleki Vareki S. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy. Cells 2021;10:1170. [PMID: 34065010 DOI: 10.3390/cells10051170] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
197 Singh HM, Leber MF, Bossow S, Engeland CE, Dessila J, Grossardt C, Zaoui K, Bell JC, Jäger D, von Kalle C, Ungerechts G. MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Mol Ther Oncolytics 2021;21:340-55. [PMID: 34141871 DOI: 10.1016/j.omto.2021.04.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Liu H, Shi Y, Qian F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Adv Drug Deliv Rev 2021;172:37-51. [PMID: 33705881 DOI: 10.1016/j.addr.2021.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
199 Liu Y, Zhou J, Li Q, Li L, Jia Y, Geng F, Zhou J, Yin T. Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma. Adv Drug Deliv Rev 2021;172:80-103. [PMID: 33705874 DOI: 10.1016/j.addr.2021.02.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
200 Mallya K, Gautam SK, Aithal A, Batra SK, Jain M. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer 2021;1876:188554. [PMID: 33945847 DOI: 10.1016/j.bbcan.2021.188554] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
201 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
202 Huang SS, Lee KJ, Chen HC, Prajnamitra RP, Hsu CH, Jian CB, Yu XE, Chueh DY, Kuo CW, Chiang TC, Choong OK, Huang SC, Beh CY, Chen LL, Lai JJ, Chen P, Kamp TJ, Tien YW, Lee HM, Hsieh PC. Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. Sci Adv 2021;7:eabf2400. [PMID: 33893103 DOI: 10.1126/sciadv.abf2400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
203 Novák Š, Kolář M, Szabó A, Vernerová Z, Lacina L, Strnad H, Šáchová J, Hradilová M, Havránek J, Španko M, Čoma M, Urban L, Kaňuchová M, Melegová N, Gürlich R, Dvořák J, Smetana K Jr, Gál P, Szabo P. Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts. Cancer Genomics Proteomics 2021;18:221-43. [PMID: 33893076 DOI: 10.21873/cgp.20254] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
204 Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers (Basel) 2021;13:2053. [PMID: 33922795 DOI: 10.3390/cancers13092053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
205 Sagara A, Nakata K, Yamashita T, Guan W, Zhong P, Matsumoto S, Endo S, Iwamoto C, Shindo K, Ikenaga N, Moriyama T, Ohuchida K, Mizumoto K, Nakamura M. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Pancreatology 2021:S1424-3903(21)00141-1. [PMID: 33965328 DOI: 10.1016/j.pan.2021.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Du J, Gu J, Li J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep 2020;40:BSR20200401. [PMID: 32677676 DOI: 10.1042/BSR20200401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
207 Feng H, Moriyama T, Ohuchida K, Sheng N, Iwamoto C, Shindo K, Shirahane K, Ikenaga N, Nagai S, Nakata K, Mizumoto K, Nakamura M. N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions. J Exp Clin Cancer Res 2021;40:133. [PMID: 33858491 DOI: 10.1186/s13046-021-01939-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Fang Y, Yu A, Ye L, Zhai G. Research progress in tumor targeted immunotherapy. Expert Opin Drug Deliv 2021;18:1067-90. [PMID: 33507117 DOI: 10.1080/17425247.2021.1882992] [Reference Citation Analysis]
209 Koltai T, Reshkin SJ, Carvalho TMA, Cardone RA. Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer. Int J Mol Sci 2021;22:3953. [PMID: 33921242 DOI: 10.3390/ijms22083953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
210 Lu P, Ma Y, Wei S, Liang X. The dual role of complement in cancers, from destroying tumors to promoting tumor development. Cytokine 2021;143:155522. [PMID: 33849765 DOI: 10.1016/j.cyto.2021.155522] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
211 Carter EP, Coetzee AS, Tomas Bort E, Wang Q, Kocher HM, Grose RP. Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. Cells 2021;10:847. [PMID: 33918004 DOI: 10.3390/cells10040847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
212 Elsayed M, Abdelrahim M. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021;9:389. [PMID: 33917380 DOI: 10.3390/biomedicines9040389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
213 Hu X, Xia F, Lee J, Li F, Lu X, Zhuo X, Nie G, Ling D. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh) 2021;8:2002545. [PMID: 33854877 DOI: 10.1002/advs.202002545] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
214 Zhao D, Jiang K, Wang Y, Cheng J, Mo F, Luo T, Guo Y, Zhang C, Song J. Out-of-the-Box Nanocapsules Packed with On-Demand Hydrophobic Anticancer Drugs for Lung Targeting, Esterase Triggering, and Synergy Therapy. Adv Healthc Mater 2021;10:e2001803. [PMID: 33433961 DOI: 10.1002/adhm.202001803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
215 Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, Guo HF, Yu J, Rodriguez BL, Firestone JJA, Mino B, Creighton CJ, Solis LM, Villalobos P, Raso MG, Sazer DW, Gibbons DL, Russell WK, Longmore GD, Wistuba II, Wang J, Chapman HA, Miller JS, Zong C, Kurie JM. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep 2021;35:109009. [PMID: 33882319 DOI: 10.1016/j.celrep.2021.109009] [Reference Citation Analysis]
216 Walter SG, Scheidt S, Nißler R, Gaisendrees C, Zarghooni K, Schildberg FA. In-Depth Characterization of Stromal Cells within the Tumor Microenvironment Yields Novel Therapeutic Targets. Cancers (Basel) 2021;13:1466. [PMID: 33806802 DOI: 10.3390/cancers13061466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
217 Su F, Daquinag AC, Ahn S, Saha A, Dai Y, Zhao Z, DiGiovanni J, Kolonin MG. Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium. NPJ Precis Oncol 2021;5:26. [PMID: 33753872 DOI: 10.1038/s41698-021-00160-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
218 Rebelo R, Polónia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 2021;14:280. [PMID: 33804613 DOI: 10.3390/ph14030280] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
219 Encarnación-Rosado J, Kimmelman AC. Harnessing metabolic dependencies in pancreatic cancers. Nat Rev Gastroenterol Hepatol 2021;18:482-92. [PMID: 33742165 DOI: 10.1038/s41575-021-00431-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
220 Shlyakhtina Y, Moran KL, Portal MM. Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution. Cancers (Basel) 2021;13:1380. [PMID: 33803675 DOI: 10.3390/cancers13061380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
221 Liu X, Li Z, Wang Y. Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Adv Biol (Weinh) 2021;5:e1900236. [PMID: 33729700 DOI: 10.1002/adbi.201900236] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
222 Huang M, Fu M, Wang J, Xia C, Zhang H, Xiong Y, He J, Liu J, Liu B, Pan S, Liu F. TGF-β1-activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial-mesenchymal transition by autophagy or overexpression of FAP-α. Biochem Pharmacol 2021;188:114527. [PMID: 33741330 DOI: 10.1016/j.bcp.2021.114527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Wei C, Tang M, Xu Z, Yang L, Lv Y. Role of endothelial cells in the regulation of mechanical microenvironment on tumor progression. Acta Mech Sin 2021;37:218-28. [DOI: 10.1007/s10409-021-01056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
224 Metcalf KJ, Alazzeh A, Werb Z, Weaver VM. Leveraging microenvironmental synthetic lethalities to treat cancer. J Clin Invest 2021;131:143765. [PMID: 33720045 DOI: 10.1172/JCI143765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
225 Boyd LNC, Andini KD, Peters GJ, Kazemier G, Giovannetti E. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. Semin Cancer Biol 2021:S1044-579X(21)00056-0. [PMID: 33737108 DOI: 10.1016/j.semcancer.2021.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
226 Schultz CW, Ruiz de Garibay G, Langer A, Liu JB, Dhir T, Leitch C, Wessner CE, Mayoral M, Zhang B, Popa M, Huang C, Kotopoulis S, Luo X, Zhen Y, Niu S, Torkzaban M, Wallace K, Eisenbrey JR, Brody JR, McCormack E, Forsberg F. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Cancer Biol Ther 2021;22:204-15. [PMID: 33691611 DOI: 10.1080/15384047.2021.1881026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
227 Mortoglou M, Wallace D, Buha Djordjevic A, Djordjevic V, Arisan ED, Uysal-onganer P. MicroRNA-Regulated Signaling Pathways: Potential Biomarkers for Pancreatic Ductal Adenocarcinoma. Stresses 2021;1:30-47. [DOI: 10.3390/stresses1010004] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
228 Shen P, Yang T, Chen Q, Yuan H, Wu P, Cai B, Meng L, Huang X, Liu J, Zhang Y, Hu W, Miao Y, Lu Z, Jiang K. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Mol Cancer 2021;20:51. [PMID: 33750389 DOI: 10.1186/s12943-021-01333-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
229 Liu X, Jiang J, Chang CH, Liao YP, Lodico JJ, Tang I, Zheng E, Qiu W, Lin M, Wang X, Ji Y, Mei KC, Nel AE, Meng H. Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy. Small 2021;17:e2005993. [PMID: 33682329 DOI: 10.1002/smll.202005993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
230 Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol 2021;14:101056. [PMID: 33684837 DOI: 10.1016/j.tranon.2021.101056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
231 Chen Y, Kim J, Yang S, Wang H, Wu CJ, Sugimoto H, LeBleu VS, Kalluri R. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 2021;39:548-565.e6. [PMID: 33667385 DOI: 10.1016/j.ccell.2021.02.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 23.0] [Reference Citation Analysis]
232 Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, Xie N. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol 2021;9:641469. [PMID: 33732706 DOI: 10.3389/fcell.2021.641469] [Cited by in Crossref: 14] [Cited by in F6Publishing: 36] [Article Influence: 14.0] [Reference Citation Analysis]
233 Liu X, Jiang J, Liao YP, Tang I, Zheng E, Qiu W, Lin M, Wang X, Ji Y, Mei KC, Liu Q, Chang CH, Wainberg ZA, Nel AE, Meng H. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh) 2021;8:2002147. [PMID: 33747719 DOI: 10.1002/advs.202002147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
234 Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, Wouters A, Lardon F, Roeyen G, Verhoeven Y, Janssens A, Vandamme T, van Dam P, Peeters M, Prenen H. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers (Basel) 2021;13:987. [PMID: 33673405 DOI: 10.3390/cancers13050987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
235 Liu AD, Zhou J, Bi XY, Hou GQ, Li SS, Chen Q, Xu H, Cao X. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. Clin Transl Med 2021;11:e337. [PMID: 33783993 DOI: 10.1002/ctm2.337] [Reference Citation Analysis]
236 Domogauer JD, de Toledo SM, Howell RW, Azzam EI. Acquired radioresistance in cancer associated fibroblasts is concomitant with enhanced antioxidant potential and DNA repair capacity. Cell Commun Signal 2021;19:30. [PMID: 33637118 DOI: 10.1186/s12964-021-00711-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
237 Josselsohn RH, Tuveson DA. Pancreatic cancer SLUGged. J Exp Med 2020;217:e20200819. [PMID: 32813872 DOI: 10.1084/jem.20200819] [Reference Citation Analysis]
238 Miyazaki Y, Oda T, Inagaki Y, Kushige H, Saito Y, Mori N, Takayama Y, Kumagai Y, Mitsuyama T, Kida YS. Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model. Sci Rep 2021;11:4690. [PMID: 33633222 DOI: 10.1038/s41598-021-84058-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
239 Di Maggio F, El-Shakankery KH. Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma: Can We Learn From Breast Cancer? Pancreas. 2020;49:313-325. [PMID: 32168249 DOI: 10.1097/mpa.0000000000001504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
240 Rodríguez Gil Y, Jiménez Sánchez P, Muñoz Velasco R, García García A, Sánchez-Arévalo Lobo VJ. Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. Int J Mol Sci 2021;22:2077. [PMID: 33669845 DOI: 10.3390/ijms22042077] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
241 Han Z, Liu G. CEST MRI trackable nanoparticle drug delivery systems. Biomed Mater 2021;16:024103. [PMID: 33470986 DOI: 10.1088/1748-605X/abdd70] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
242 Cox TR. The matrix in cancer. Nat Rev Cancer 2021;21:217-38. [PMID: 33589810 DOI: 10.1038/s41568-020-00329-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 123] [Article Influence: 28.0] [Reference Citation Analysis]
243 Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers (Basel) 2021;13:799. [PMID: 33672917 DOI: 10.3390/cancers13040799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
244 Farag MM, Abd El Malak NS, Yehia SA, Ahmed MA. Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment. Int J Nanomedicine 2021;16:1005-19. [PMID: 33603365 DOI: 10.2147/IJN.S297634] [Reference Citation Analysis]
245 Wang J, Bao Y, Yao Y. Application of Bionanomaterials in Tumor Immune Microenvironment Therapy. J Immunol Res 2021;2021:6663035. [PMID: 33628850 DOI: 10.1155/2021/6663035] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
246 Brundel DH, Feeney OM, Nowell CJ, Suys EJ, Gracia G, Kaminskas LM, McIntosh MM, Kang DW, Porter CJ. Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration. Nanomedicine (Lond) 2021;16:275-92. [PMID: 33560142 DOI: 10.2217/nnm-2020-0433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020;130:4704-4709. [PMID: 32749238 DOI: 10.1172/jci136760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 47] [Article Influence: 20.0] [Reference Citation Analysis]
248 Noë M, Hong SM, Wood LD, Thompson ED, Roberts NJ, Goggins MG, Klein AP, Eshleman JR, Kern SE, Hruban RH. Pancreatic cancer pathology viewed in the light of evolution. Cancer Metastasis Rev 2021. [PMID: 33555482 DOI: 10.1007/s10555-020-09953-z] [Reference Citation Analysis]
249 Luo D, Digiovanni MG, Wei R, Lacomb JF, Williams JL, Rigas B, Mackenzie GG. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis 2020;41:927-39. [PMID: 31584613 DOI: 10.1093/carcin/bgz170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
250 Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, Johnson BD, Dwinell MB. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. Cell Mol Gastroenterol Hepatol 2021;12:41-58. [PMID: 33548597 DOI: 10.1016/j.jcmgh.2021.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
251 Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol 2020;11:629722. [PMID: 33597954 DOI: 10.3389/fimmu.2020.629722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
252 Munir H, Jones JO, Janowitz T, Hoffmann M, Euler M, Martins CP, Welsh SJ, Shields JD. Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth. Nat Commun 2021;12:683. [PMID: 33514748 DOI: 10.1038/s41467-021-20982-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
253 Waghmare MN, Qureshi TS, Krishna CM, Pansare K, Gadewal N, Hole A, Dongre PM. β-Lactoglobulin-gold nanoparticles interface and its interaction with some anticancer drugs - an approach for targeted drug delivery. J Biomol Struct Dyn 2021;:1-25. [PMID: 33509048 DOI: 10.1080/07391102.2021.1879270] [Reference Citation Analysis]
254 Hofschröer V, Najder K, Rugi M, Bouazzi R, Cozzolino M, Arcangeli A, Panyi G, Schwab A. Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy. Front Pharmacol 2020;11:586599. [PMID: 33841132 DOI: 10.3389/fphar.2020.586599] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
255 Elliott RO, He M. Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. Pharmaceutics 2021;13:122. [PMID: 33477972 DOI: 10.3390/pharmaceutics13010122] [Cited by in Crossref: 9] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
256 Katsube R, Noma K, Ohara T, Nishiwaki N, Kobayashi T, Komoto S, Sato H, Kashima H, Kato T, Kikuchi S, Tazawa H, Kagawa S, Shirakawa Y, Kobayashi H, Fujiwara T. Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer. Sci Rep 2021;11:1693. [PMID: 33462372 DOI: 10.1038/s41598-021-81465-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
257 Wu Y, Zhang C, Jiang K, Werner J, Bazhin AV, D'Haese JG. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Front Oncol 2020;10:621937. [PMID: 33520728 DOI: 10.3389/fonc.2020.621937] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
258 Liu S, Ren J, Ten Dijke P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther 2021;6:8. [PMID: 33414388 DOI: 10.1038/s41392-020-00436-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 69] [Article Influence: 18.0] [Reference Citation Analysis]
259 Gamradt P, De La Fouchardière C, Hennino A. Stromal Protein-Mediated Immune Regulation in Digestive Cancers. Cancers (Basel) 2021;13:E146. [PMID: 33466303 DOI: 10.3390/cancers13010146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
260 Rocha FG. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:1400-6. [PMID: 33386541 DOI: 10.1245/s10434-020-09367-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
261 Li Y, Zhao Z, Lin CY, Liu Y, Staveley-OCarroll KF, Li G, Cheng K. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. Theranostics 2021;11:2182-200. [PMID: 33500719 DOI: 10.7150/thno.53102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
262 Suri R, Zimmerman JW, Burkhart RA. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. Ann Pancreat Cancer 2020;3:17. [PMID: 33889840 DOI: 10.21037/apc-20-29] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Bushnell GG, Orbach SM, Ma JA, Crawford HC, Wicha MS, Jeruss JS, Shea LD. Disease-induced immunomodulation at biomaterial scaffolds detects early pancreatic cancer in a spontaneous model. Biomaterials 2021;269:120632. [PMID: 33418200 DOI: 10.1016/j.biomaterials.2020.120632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
264 Nia HT, Munn LL, Jain RK. Physical traits of cancer. Science 2020;370:eaaz0868. [PMID: 33122355 DOI: 10.1126/science.aaz0868] [Cited by in Crossref: 53] [Cited by in F6Publishing: 115] [Article Influence: 26.5] [Reference Citation Analysis]
265 Novizio N, Belvedere R, Pessolano E, Tosco A, Porta A, Perretti M, Campiglia P, Filippelli A, Petrella A. Annexin A1 Released in Extracellular Vesicles by Pancreatic Cancer Cells Activates Components of the Tumor Microenvironment, through Interaction with the Formyl-Peptide Receptors. Cells 2020;9:E2719. [PMID: 33353163 DOI: 10.3390/cells9122719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
266 Kim E, Choi S, Kang B, Kong J, Kim Y, Yoon WH, Lee H, Kim S, Kim H, Lee H, Yang C, Lee YJ, Kang M, Roh T, Jung S, Kim S, Ku JH, Shin K. Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature 2020;588:664-9. [DOI: 10.1038/s41586-020-3034-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
267 Sunami Y, Häußler J, Kleeff J. Cellular Heterogeneity of Pancreatic Stellate Cells, Mesenchymal Stem Cells, and Cancer-Associated Fibroblasts in Pancreatic Cancer. Cancers (Basel) 2020;12:E3770. [PMID: 33333727 DOI: 10.3390/cancers12123770] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
268 Sandha KK, Shukla MK, Gupta PN. Recent Advances in Strategies for Extracellular Matrix Degradation and Synthesis Inhibition for Improved Therapy of Solid Tumors. CPD 2020;26:5456-67. [DOI: 10.2174/1381612826666200728141601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Yu Y, Schuck K, Friess H, Kong B. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer. Expert Opin Ther Targets 2021;25:5-13. [PMID: 33246383 DOI: 10.1080/14728222.2021.1857727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
270 Grauel AL, Nguyen B, Ruddy D, Laszewski T, Schwartz S, Chang J, Chen J, Piquet M, Pelletier M, Yan Z, Kirkpatrick ND, Wu J, deWeck A, Riester M, Hims M, Geyer FC, Wagner J, MacIsaac K, Deeds J, Diwanji R, Jayaraman P, Yu Y, Simmons Q, Weng S, Raza A, Minie B, Dostalek M, Chikkegowda P, Ruda V, Iartchouk O, Chen N, Thierry R, Zhou J, Pruteanu-Malinici I, Fabre C, Engelman JA, Dranoff G, Cremasco V. TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. Nat Commun 2020;11:6315. [PMID: 33298926 DOI: 10.1038/s41467-020-19920-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
271 Takahashi R, Ijichi H, Sano M, Miyabayashi K, Mohri D, Kim J, Kimura G, Nakatsuka T, Fujiwara H, Yamamoto K, Kudo Y, Tanaka Y, Tateishi K, Nakai Y, Morishita Y, Soma K, Takeda N, Moses HL, Isayama H, Koike K. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Sci Rep 2020;10:21194. [PMID: 33273652 DOI: 10.1038/s41598-020-78320-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
272 Cao L, Wu J, Qu X, Sheng J, Cui M, Liu S, Huang X, Xiang Y, Li B, Zhang X, Cui R. Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications. J Exp Clin Cancer Res 2020;39:267. [PMID: 33256814 DOI: 10.1186/s13046-020-01765-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
273 Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater 2021;20:548-59. [PMID: 33257795 DOI: 10.1038/s41563-020-00849-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
274 Yang Y, Guo Z, Chen W, Wang X, Cao M, Han X, Zhang K, Teng B, Cao J, Wu W, Cao P, Huang C, Qiu Z. M2 Macrophage-Derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2. Mol Ther 2021;29:1226-38. [PMID: 33221435 DOI: 10.1016/j.ymthe.2020.11.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
275 Rahi S, Mehan S. Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals. Cell Mol Neurobiol 2020. [PMID: 33206287 DOI: 10.1007/s10571-020-01010-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
276 Zhao Y, Ye F, Brismar TB, Li X, He R, Heuchel R, El-Sayed R, Feliu N, Zheng W, Oerther S, Dutta J, Parak WJ, Muhammed M, Hassan M. Multimodal Imaging of Pancreatic Ductal Adenocarcinoma Using Multifunctional Nanoparticles as Contrast Agents. ACS Appl Mater Interfaces 2020. [PMID: 33201660 DOI: 10.1021/acsami.0c15430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
277 Grbovic-Huezo O, Pitter KL, Lecomte N, Saglimbeni J, Askan G, Holm M, Melchor JP, Chandwani R, Joshi S, Haglund C, Iacobuzio-Donahue CA, Chiosis G, Tammela T, Leach SD. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2020;117:30670-8. [PMID: 33199632 DOI: 10.1073/pnas.1920240117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
278 Garcia PE, Scales MK, Allen BL, Pasca di Magliano M. Pancreatic Fibroblast Heterogeneity: From Development to Cancer. Cells 2020;9:E2464. [PMID: 33198201 DOI: 10.3390/cells9112464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
279 Li T, Wan M, Mao C. Research Progress of Micro/Nanomotors for Cancer Treatment. Chempluschem 2020;85:2586-98. [PMID: 33174354 DOI: 10.1002/cplu.202000532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
280 Krishnamoorthy M, Lenehan JG, Burton JP, Maleki Vareki S. Immunomodulation in Pancreatic Cancer. Cancers (Basel) 2020;12:E3340. [PMID: 33198059 DOI: 10.3390/cancers12113340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
281 Vonderheide RH, Bear AS. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Front Immunol 2020;11:605619. [PMID: 33304355 DOI: 10.3389/fimmu.2020.605619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
282 Selvanesan BC, Meena K, Beck A, Meheus L, Lara O, Rooman I, Gravekamp C. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. J Immunother Cancer 2020;8:e001250. [PMID: 33154149 DOI: 10.1136/jitc-2020-001250] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
283 Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer 2021;1875:188461. [PMID: 33157162 DOI: 10.1016/j.bbcan.2020.188461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
284 Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, Öhlund D, Regel I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers (Basel) 2020;12:E3234. [PMID: 33147766 DOI: 10.3390/cancers12113234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
285 Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer 2021;21:37-50. [PMID: 33128031 DOI: 10.1038/s41568-020-00308-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 135] [Article Influence: 20.5] [Reference Citation Analysis]
286 Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, Wagner J, Muir A, Lau AN, Gabitova L, Pazina T, Gupta S, Luong T, Rollins D, Malik R, Thapa RJ, Restifo D, Zhou Y, Cai KQ, Hensley HH, Tan Y, Kruger WD, Devarajan K, Balachandran S, Klein-Szanto AJ, Wang H, El-Deiry WS, Vander Heiden MG, Peri S, Campbell KS, Astsaturov I, Cukierman E. Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and Immunosuppression. Cancer Discov 2021;11:446-79. [PMID: 33127842 DOI: 10.1158/2159-8290.CD-20-0775] [Cited by in Crossref: 17] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
287 Yang Y, Huynh N, Dumesny C, Wang K, He H, Nikfarjam M. Cannabinoids Inhibited Pancreatic Cancer via P-21 Activated Kinase 1 Mediated Pathway. Int J Mol Sci 2020;21:E8035. [PMID: 33126623 DOI: 10.3390/ijms21218035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
288 Mandili G, Curcio C, Bulfamante S, Follia L, Ferrero G, Mazza E, Principe M, Cordero F, Satolli MA, Spadi R, Evangelista A, Giordano D, Viet D, Cappello P, Novelli F. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J Immunother Cancer 2020;8:e001071. [PMID: 33115943 DOI: 10.1136/jitc-2020-001071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
289 Karimnia V, Rizvi I, Slack FJ, Celli JP. Photodestruction of Stromal Fibroblasts Enhances Tumor Response to PDT in 3D Pancreatic Cancer Coculture Models. Photochem Photobiol 2021;97:416-26. [PMID: 33011973 DOI: 10.1111/php.13339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
290 Kim GP, Surinach A, Corvino FA, Cockrum P, Belanger B, Abushahin L. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Future Oncol 2021;17:675-88. [PMID: 33070660 DOI: 10.2217/fon-2020-0902] [Reference Citation Analysis]
291 Steinberg E, Orehov N, Tischenko K, Schwob O, Zamir G, Hubert A, Manevitch Z, Benny O. Rapid Clearing for High Resolution 3D Imaging of Ex Vivo Pancreatic Cancer Spheroids. Int J Mol Sci 2020;21:E7703. [PMID: 33081011 DOI: 10.3390/ijms21207703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
292 Guo Y, Tong Y, Zhu H, Xiao Y, Guo H, Shang L, Zheng W, Ma S, Liu X, Bai Y. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways. Cell Biol Toxicol 2021;37:479-96. [PMID: 33070227 DOI: 10.1007/s10565-020-09562-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
293 Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?Front Oncol. 2020;10:576399. [PMID: 33178608 DOI: 10.3389/fonc.2020.576399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
294 Hilmi M, Nicolle R, Bousquet C, Neuzillet C. Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion. Cancers (Basel) 2020;12:E2969. [PMID: 33066357 DOI: 10.3390/cancers12102969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
295 Delma MI. Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma? Cureus 2020;12:e10909. [PMID: 33194476 DOI: 10.7759/cureus.10909] [Reference Citation Analysis]
296 Mejia I, Bodapati S, Chen KT, Díaz B. Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. Biomedicines 2020;8:E401. [PMID: 33050151 DOI: 10.3390/biomedicines8100401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Zaghdoudi S, Decaup E, Belhabib I, Samain R, Cassant-Sourdy S, Rochotte J, Brunel A, Schlaepfer D, Cros J, Neuzillet C, Strehaiano M, Alard A, Tomasini R, Rajeeve V, Perraud A, Mathonnet M, Pearce OM, Martineau Y, Pyronnet S, Bousquet C, Jean C. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. EMBO Mol Med. 2020;12:e12010. [PMID: 33025708 DOI: 10.15252/emmm.202012010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
298 Han X, Zhang WH, Wang WQ, Yu XJ, Liu L. Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. Biochim Biophys Acta Rev Cancer 2020;1874:188444. [PMID: 33031899 DOI: 10.1016/j.bbcan.2020.188444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
299 Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews 2020;100:1707-51. [DOI: 10.1152/physrev.00042.2019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
300 Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, Engleitner T, Öllinger R, Nomura A, Wirges N, Papargyriou A, Jahan Sarker RS, Ranjan RA, Dantes Z, Weichert W, Rustgi AK, Schmid RM, Rad R, Schneider G, Saur D, Reichert M. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Gastroenterology 2021;160:346-361.e24. [PMID: 33007300 DOI: 10.1053/j.gastro.2020.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
301 Sinha D, Smith C, Khanna R. Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. Trends Mol Med 2021;27:75-90. [PMID: 33011081 DOI: 10.1016/j.molmed.2020.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Yao H, Sun L, Li J, Zhou X, Li R, Shao R, Zhang Y, Li L. A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells. Int J Nanomedicine 2020;15:7013-34. [PMID: 33061365 DOI: 10.2147/IJN.S260163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
303 Ebelt ND, Zamloot V, Manuel ER. Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy. Oncotarget 2020;11:3486-8. [PMID: 33014284 DOI: 10.18632/oncotarget.27745] [Reference Citation Analysis]
304 Jeng KS, Sheen IS, Leu CM, Tseng PH, Chang CF. The Role of Smoothened in Cancer. Int J Mol Sci 2020;21:E6863. [PMID: 32962123 DOI: 10.3390/ijms21186863] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
305 Bear AS, Vonderheide RH, O'Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell 2020;38:788-802. [PMID: 32946773 DOI: 10.1016/j.ccell.2020.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
306 Ganguly D, Chandra R, Karalis J, Teke M, Aguilera T, Maddipati R, Wachsmann MB, Ghersi D, Siravegna G, Zeh HJ 3rd, Brekken R, Ting DT, Ligorio M. Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. Cancers (Basel) 2020;12:E2652. [PMID: 32957515 DOI: 10.3390/cancers12092652] [Cited by in Crossref: 13] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
307 Ge Y, Ye F, Liu J, Yang J, Spannenberg A, Jiao H, Jackstell R, Beller M. Ligand-Controlled Palladium-Catalyzed Carbonylation of Alkynols: Highly Selective Synthesis of α-Methylene-β-Lactones. Angew Chem Int Ed Engl 2020;59:21585-90. [PMID: 32573055 DOI: 10.1002/anie.202006550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
308 Ge Y, Ye F, Liu J, Yang J, Spannenberg A, Jiao H, Jackstell R, Beller M. Ligand‐Controlled Palladium‐Catalyzed Carbonylation of Alkynols: Highly Selective Synthesis of α‐Methylene‐β‐Lactones. Angew Chem 2020;132:21769-74. [DOI: 10.1002/ange.202006550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
309 Tian H, Lyu Y, Yang YG, Hu Z. Humanized Rodent Models for Cancer Research. Front Oncol 2020;10:1696. [PMID: 33042811 DOI: 10.3389/fonc.2020.01696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
310 Greene MK, Chen T, Robinson E, Straubinger NL, Minx C, Chan DKW, Wang J, Burrows JF, Van Schaeybroeck S, Baker JR, Caddick S, Longley DB, Mager DE, Straubinger RM, Chudasama V, Scott CJ. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. Br J Cancer 2020;123:1502-12. [PMID: 32913288 DOI: 10.1038/s41416-020-01046-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
311 Moon HR, Ozcelikkale A, Yang Y, Elzey BD, Konieczny SF, Han B. An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations. Lab Chip 2020;20:3720-32. [PMID: 32909573 DOI: 10.1039/d0lc00707b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
312 Schlesinger Y, Yosefov-Levi O, Kolodkin-Gal D, Granit RZ, Peters L, Kalifa R, Xia L, Nasereddin A, Shiff I, Amran O, Nevo Y, Elgavish S, Atlan K, Zamir G, Parnas O. Single-cell transcriptomes of pancreatic preinvasive lesions and cancer reveal acinar metaplastic cells' heterogeneity. Nat Commun 2020;11:4516. [PMID: 32908137 DOI: 10.1038/s41467-020-18207-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
313 Wei Y, Song S, Duan N, Wang F, Wang Y, Yang Y, Peng C, Li J, Nie D, Zhang X, Guo S, Zhu C, Yu M, Gan Y. MT1-MMP-Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy. Adv Sci (Weinh) 2020;7:1902746. [PMID: 32995113 DOI: 10.1002/advs.201902746] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
314 Jones JO, Moody WM, Shields JD. Microenvironmental modulation of the developing tumour: an immune-stromal dialogue. Mol Oncol 2021;15:2600-33. [PMID: 32741067 DOI: 10.1002/1878-0261.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
315 Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno NT, Kolonin MG. Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Mol Ther Oncolytics 2020;18:579-86. [PMID: 32995482 DOI: 10.1016/j.omto.2020.08.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
316 Guo Z, Wang X, Yang Y, Chen W, Zhang K, Teng B, Huang C, Zhao Q, Qiu Z. Hypoxic Tumor-Derived Exosomal Long Noncoding RNA UCA1 Promotes Angiogenesis via miR-96-5p/AMOTL2 in Pancreatic Cancer. Mol Ther Nucleic Acids. 2020;22:179-195. [PMID: 32942233 DOI: 10.1016/j.omtn.2020.08.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
317 Hadden M, Mittal A, Samra J, Zreiqat H, Sahni S, Ramaswamy Y. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression.BiochimBiophysActa Rev Cancer. 2020;1874:188418. [PMID: 32827581 DOI: 10.1016/j.bbcan.2020.188418] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
318 Jena BC, Das CK, Bharadwaj D, Mandal M. Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression. Biochim Biophys Acta Rev Cancer 2020;1874:188416. [PMID: 32822826 DOI: 10.1016/j.bbcan.2020.188416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
319 Turaga RC, Sharma M, Mishra F, Krasinskas A, Yuan Y, Yang JJ, Wang S, Liu C, Li S, Liu ZR. Modulation of Cancer-Associated Fibrotic Stroma by An Integrin αvβ3 Targeting Protein for Pancreatic Cancer Treatment. Cell Mol Gastroenterol Hepatol 2021;11:161-79. [PMID: 32810598 DOI: 10.1016/j.jcmgh.2020.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
320 Bu L, Baba H, Yasuda T, Uchihara T, Ishimoto T. Functional diversity of cancer-associated fibroblasts in modulating drug resistance. Cancer Sci 2020;111:3468-77. [PMID: 33044028 DOI: 10.1111/cas.14578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
321 Munir H, Mazzaglia C, Shields JD. Stromal regulation of tumor-associated lymphatics. Adv Drug Deliv Rev 2020;161-162:75-89. [PMID: 32783989 DOI: 10.1016/j.addr.2020.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
322 Tanase C, Gheorghisan-Galateanu AA, Popescu ID, Mihai S, Codrici E, Albulescu R, Hinescu ME. CD36 and CD97 in Pancreatic Cancer versus Other Malignancies. Int J Mol Sci 2020;21:E5656. [PMID: 32781778 DOI: 10.3390/ijms21165656] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
323 Sodergren MH, Mangal N, Wasan H, Sadanandam A, Balachandran VP, Jiao LR, Habib N. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J Cancer Res Clin Oncol 2020;146:2897-911. [PMID: 32748119 DOI: 10.1007/s00432-020-03332-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
324 Zhou Y, Zhou W, Chen X, Wang Q, Li C, Chen Q, Zhang Y, Lu Y, Ding X, Jiang C. Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharm Sin B 2020;10:1563-75. [PMID: 32963950 DOI: 10.1016/j.apsb.2019.11.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 19.5] [Reference Citation Analysis]
325 Yamamoto J, Miyake K, Han Q, Tan Y, Inubushi S, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Homma Y, Matsuyama R, Chawla SP, Bouvet M, Singh SR, Endo I, Hoffman RM. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett 2020;492:174-84. [PMID: 32739322 DOI: 10.1016/j.canlet.2020.07.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
326 Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagalà C, Inzani F, Russo A, Chiantera V, Pacelli F. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Ther Adv Med Oncol 2020;12:1758835920940887. [PMID: 32782488 DOI: 10.1177/1758835920940887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
327 Chen Y, Wang L, Luo S, Hu J, Huang X, Li PW, Zhang Y, Wu C, Tian BL. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. Drug Des Devel Ther 2020;14:2945-57. [PMID: 32801636 DOI: 10.2147/DDDT.S261017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Strapcova S, Takacova M, Csaderova L, Martinelli P, Lukacikova L, Gal V, Kopacek J, Svastova E. Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions. Cancers (Basel) 2020;12:E2005. [PMID: 32707920 DOI: 10.3390/cancers12082005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
329 He M, Henderson M, Muth S, Murphy A, Zheng L. Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. Ann Pancreat Cancer 2020;3:7. [PMID: 32832900 DOI: 10.21037/apc.2020.03.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
330 Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, Giri B, Ferrantella A, Dudeja V, Saluja A, Banerjee S. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest 2020;130:451-65. [PMID: 31613799 DOI: 10.1172/JCI127515] [Cited by in Crossref: 39] [Cited by in F6Publishing: 68] [Article Influence: 19.5] [Reference Citation Analysis]
331 Buchholz SM, Goetze RG, Singh SK, Ammer-Herrmenau C, Richards FM, Jodrell DI, Buchholz M, Michl P, Ellenrieder V, Hessmann E, Neesse A. Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer. Cancers (Basel) 2020;12:E1978. [PMID: 32698524 DOI: 10.3390/cancers12071978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
332 Minici C, Rigamonti E, Lanzillotta M, Monno A, Rovati L, Maehara T, Kaneko N, Deshpande V, Protti MP, De Monte L, Scielzo C, Crippa S, Arcidiacono PG, Dugnani E, Piemonti L, Falconi M, Pillai S, Manfredi AA, Della-Torre E. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Oncoimmunology 2020;9:1794359. [PMID: 32923157 DOI: 10.1080/2162402X.2020.1794359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
333 Melissari MT, Chalkidi N, Sarris ME, Koliaraki V. Fibroblast Reprogramming in Gastrointestinal Cancer. Front Cell Dev Biol 2020;8:630. [PMID: 32760726 DOI: 10.3389/fcell.2020.00630] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
334 Carr RM, Duma N, McCleary-Wheeler AL, Almada LL, Marks DL, Graham RP, Smyrk TC, Lowe V, Borad MJ, Kim G, Johnson GB, Allred JB, Yin J, Lim VS, Bekaii-Saab T, Ma WW, Erlichman C, Adjei AA, Fernandez-Zapico ME. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology 2020;20:1115-22. [PMID: 32778368 DOI: 10.1016/j.pan.2020.06.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
335 Reticker-Flynn NE, Engleman EG. Cancer systems immunology. Elife 2020;9:e53839. [PMID: 32657757 DOI: 10.7554/eLife.53839] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
336 Lau AN, Li Z, Danai LV, Westermark AM, Darnell AM, Ferreira R, Gocheva V, Sivanand S, Lien EC, Sapp KM, Mayers JR, Biffi G, Chin CR, Davidson SM, Tuveson DA, Jacks T, Matheson NJ, Yilmaz O, Vander Heiden MG. Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. Elife 2020;9:e56782. [PMID: 32648540 DOI: 10.7554/eLife.56782] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
337 Russell J, Grkovski M, O'Donoghue IJ, Kalidindi TM, Pillarsetty N, Burnazi EM, Kulick A, Bahr A, Chang Q, LeKaye HC, de Stanchina E, Yu KH, Humm JL. Predicting Gemcitabine Delivery by 18F-FAC PET in Murine Models of Pancreatic Cancer. J Nucl Med 2021;62:195-200. [PMID: 32646874 DOI: 10.2967/jnumed.120.246926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
338 Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics 2020;10:8721-43. [PMID: 32754274 DOI: 10.7150/thno.41648] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 20.5] [Reference Citation Analysis]
339 Montemagno C, Pagès G. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Front Cell Dev Biol 2020;8:584. [PMID: 32775327 DOI: 10.3389/fcell.2020.00584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
340 Takehara M, Sato Y, Kimura T, Noda K, Miyamoto H, Fujino Y, Miyoshi J, Nakamura F, Wada H, Bando Y, Ikemoto T, Shimada M, Muguruma N, Takayama T. Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. Cancer Sci 2020;111:2883-94. [PMID: 32535957 DOI: 10.1111/cas.14527] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
341 Huo D, Jiang X, Hu Y. Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management. Adv Mater 2020;32:e1904337. [PMID: 31663198 DOI: 10.1002/adma.201904337] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 25.0] [Reference Citation Analysis]
342 Sun B, Hyun H, Li LT, Wang AZ. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. Acta Pharmacol Sin 2020;41:970-85. [PMID: 32424240 DOI: 10.1038/s41401-020-0424-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
343 Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol 2020;215:610-6. [PMID: 32755156 DOI: 10.2214/AJR.19.22462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
344 Shankara Narayanan JS, Vicente DA, Ray P, Chai LF, Erdem S, Carr MJ, Capacio BA, Cox BF, Jaroch DB, Katz SC, White RR. Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. Surgery 2020;168:448-56. [PMID: 32620306 DOI: 10.1016/j.surg.2020.04.059] [Reference Citation Analysis]
345 Mayer P, Jiang Y, Kuder TA, Bergmann F, Khristenko E, Steinle V, Kaiser J, Hackert T, Kauczor HU, Klauß M, Gaida MM. Diffusion Kurtosis Imaging-A Superior Approach to Assess Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1656. [PMID: 32580519 DOI: 10.3390/cancers12061656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
346 Liu Y, Bailey JT, Abu-Laban M, Li S, Chen C, Glick AB, Hayes DJ. Photocontrolled miR-148b nanoparticles cause apoptosis, inflammation and regression of Ras induced epidermal squamous cell carcinomas in mice. Biomaterials 2020;256:120212. [PMID: 32736169 DOI: 10.1016/j.biomaterials.2020.120212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
347 Das M, Li J, Bao M, Huang L. Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer. AAPS J 2020;22:88. [PMID: 32572645 DOI: 10.1208/s12248-020-00467-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
348 Li TJ, Wang WQ, Yu XJ, Liu L. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2020;1874:188384. [PMID: 32531324 DOI: 10.1016/j.bbcan.2020.188384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
349 Nyström H. Extracellular matrix proteins in metastases to the liver - Composition, function and potential applications. Semin Cancer Biol 2021;71:134-42. [PMID: 32526353 DOI: 10.1016/j.semcancer.2020.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
350 Samonig L, Loipetzberger A, Blöchl C, Rurik M, Kohlbacher O, Aberger F, Huber CG. Proteins and Molecular Pathways Relevant for the Malignant Properties of Tumor-Initiating Pancreatic Cancer Cells. Cells 2020;9:E1397. [PMID: 32503348 DOI: 10.3390/cells9061397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
351 Ma L, Han X, Gu J, Li J, Lou W, Jin C, Saiyin H. The physiological characteristics of the basal microvilli microvessels in pancreatic cancers. Cancer Med 2020;9:5535-45. [PMID: 32488986 DOI: 10.1002/cam4.3177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
352 Peng C, Huang Y, Zheng J. Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance. Journal of Controlled Release 2020;322:64-80. [DOI: 10.1016/j.jconrel.2020.03.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
353 Katsuta E, Rashid OM, Takabe K. Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E3890. [PMID: 32485981 DOI: 10.3390/ijms21113890] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
354 Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev 2021;101:147-76. [PMID: 32466724 DOI: 10.1152/physrev.00048.2019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 19.0] [Reference Citation Analysis]
355 Henze J, Tacke F, Hardt O, Alves F, Al Rawashdeh W. Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1389. [PMID: 32481570 DOI: 10.3390/cancers12061389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
356 Norberg KJ, Liu X, Fernández Moro C, Strell C, Nania S, Blümel M, Balboni A, Bozóky B, Heuchel RL, Löhr JM. A novel pancreatic tumour and stellate cell 3D co-culture spheroid model. BMC Cancer 2020;20:475. [PMID: 32460715 DOI: 10.1186/s12885-020-06867-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
357 Zubair H, Khan MA, Anand S, Srivastava SK, Singh S, Singh AP. Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy. Semin Cancer Biol 2020:S1044-579X(20)30105-X. [PMID: 32470379 DOI: 10.1016/j.semcancer.2020.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
358 Schipper J, Westerhuis JJ, Beddows I, Madaj Z, Monsma D, Hostetter G, Kiupel M, Conejo-Garcia JR, Sempere LF. Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. Int J Cancer 2020;147:2265-78. [PMID: 32388866 DOI: 10.1002/ijc.33041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
359 Awaji M, Saxena S, Wu L, Prajapati DR, Purohit A, Varney ML, Kumar S, Rachagani S, Ly QP, Jain M, Batra SK, Singh RK. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. FASEB J 2020;34:9405-18. [PMID: 32453916 DOI: 10.1096/fj.201902990R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
360 Fujikura K, Hutchings D, Braxton AM, Zhu Q, Laheru DA, Hruban RH, Thompson ED, Wood LD. Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Mod Pathol 2020;33:2026-34. [PMID: 32457408 DOI: 10.1038/s41379-020-0572-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
361 Quoc Lam B, Shrivastava SK, Shrivastava A, Shankar S, Srivastava RK. The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives. J Cell Mol Med 2020;24:7706-16. [PMID: 32458441 DOI: 10.1111/jcmm.15413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
362 Norton J, Foster D, Chinta M, Titan A, Longaker M. Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment. Cancers (Basel) 2020;12:E1347. [PMID: 32466266 DOI: 10.3390/cancers12051347] [Cited by in Crossref: 17] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
363 Garcia PE, Adoumie M, Kim EC, Zhang Y, Scales MK, El-Tawil YS, Shaikh AZ, Wen HJ, Bednar F, Allen BL, Wellik DM, Crawford HC, Pasca di Magliano M. Differential Contribution of Pancreatic Fibroblast Subsets to the Pancreatic Cancer Stroma. Cell Mol Gastroenterol Hepatol 2020;10:581-99. [PMID: 32454112 DOI: 10.1016/j.jcmgh.2020.05.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
364 Garcia PL, Miller AL, Yoon KJ. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers (Basel) 2020;12:E1327. [PMID: 32456018 DOI: 10.3390/cancers12051327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
365 Bausch D, Fritz S, Bolm L, Wellner UF, Fernandez-Del-Castillo C, Warshaw AL, Thayer SP, Liss AS. Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer. Angiogenesis 2020;23:479-92. [PMID: 32444947 DOI: 10.1007/s10456-020-09725-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
366 Hauge A, Rofstad EK. Antifibrotic therapy to normalize the tumor microenvironment. J Transl Med 2020;18:207. [PMID: 32434573 DOI: 10.1186/s12967-020-02376-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
367 Mehta A, Hwang WL, Weekes C. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Ann Pancreat Cancer 2020;3:3. [PMID: 33294843 DOI: 10.21037/apc-2020-pda-05] [Reference Citation Analysis]
368 Huang H, Brekken RA. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. Am J Physiol Cell Physiol 2020;319:C233-43. [PMID: 32432930 DOI: 10.1152/ajpcell.00079.2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
369 Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol 2020;91-92:8-18. [PMID: 32442601 DOI: 10.1016/j.matbio.2020.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
370 Horwitz MA, Robins JG, Johnson JS. De Novo Synthesis of the DEF-Ring Stereotriad Core of the Veratrum Alkaloids. J Org Chem 2020;85:6808-14. [PMID: 32352768 DOI: 10.1021/acs.joc.0c00685] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
371 Nelson SR, Walsh N. Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. Cancers (Basel) 2020;12:E1233. [PMID: 32423157 DOI: 10.3390/cancers12051233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
372 Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol 2020;17:527-40. [PMID: 32398706 DOI: 10.1038/s41571-020-0363-5] [Cited by in Crossref: 82] [Cited by in F6Publishing: 239] [Article Influence: 41.0] [Reference Citation Analysis]
373 Ferguson S, Weissleder R. Modeling EV Kinetics for Use in Early Cancer Detection. Adv Biosyst 2020;4:e1900305. [PMID: 32394646 DOI: 10.1002/adbi.201900305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
374 Tschumperlin DJ, Lagares D. Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma. Pharmacol Ther 2020;212:107575. [PMID: 32437826 DOI: 10.1016/j.pharmthera.2020.107575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
375 Madamsetty VS, Pal K, Dutta SK, Wang E, Mukhopadhyay D. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1189. [PMID: 32397114 DOI: 10.3390/cancers12051189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
376 Yamasaki A, Yanai K, Onishi H. Hypoxia and pancreatic ductal adenocarcinoma. Cancer Lett 2020;484:9-15. [PMID: 32380129 DOI: 10.1016/j.canlet.2020.04.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
377 Stopa KB, Kusiak AA, Szopa MD, Ferdek PE, Jakubowska MA. Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies. Int J Mol Sci 2020;21:E3218. [PMID: 32370075 DOI: 10.3390/ijms21093218] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
378 Khan MA, Srivastava SK, Zubair H, Patel GK, Arora S, Khushman M, Carter JE, Gorman GS, Singh S, Singh AP. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. J Biol Chem 2020;295:8413-24. [PMID: 32358063 DOI: 10.1074/jbc.RA119.011748] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
379 Corrie PG, Qian W, Basu B, Valle JW, Falk S, Lwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J, Arif S, Bridgewater J, Propper D, Gillmore R, Gopinathan A, Skells R, Bundi P, Brais R, Dalchau K, Bax L, Chhabra A, Machin A, Dayim A, McAdam K, Cummins S, Wall L, Ellis R, Anthoney A, Evans J, Ma YT, Isherwood C, Neesse A, Tuveson D, Jodrell DI. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer 2020;122:1760-8. [PMID: 32350413 DOI: 10.1038/s41416-020-0846-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
380 Lee E, Yeo SY, Lee KW, Lee JA, Kim KK, Kim SH. New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts. Sci Rep 2020;10:7058. [PMID: 32341496 DOI: 10.1038/s41598-020-63996-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
381 Somerville TD, Biffi G, Daßler-Plenker J, Hur SK, He XY, Vance KE, Miyabayashi K, Xu Y, Maia-Silva D, Klingbeil O, Demerdash OE, Preall JB, Hollingsworth MA, Egeblad M, Tuveson DA, Vakoc CR. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. Elife 2020;9:e53381. [PMID: 32329713 DOI: 10.7554/eLife.53381] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
382 Ruggeri JM, Franco-Barraza J, Sohail A, Zhang Y, Long D, Pasca di Magliano M, Cukierman E, Fridman R, Crawford HC. Discoidin Domain Receptor 1 (DDR1) Is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma. Am J Pathol 2020;190:1735-51. [PMID: 32339496 DOI: 10.1016/j.ajpath.2020.03.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
383 Berretta M, Bignucolo A, Di Francia R, Comello F, Facchini G, Ceccarelli M, Iaffaioli RV, Quagliariello V, Maurea N. Resveratrol in Cancer Patients: From Bench to Bedside. Int J Mol Sci 2020;21:E2945. [PMID: 32331450 DOI: 10.3390/ijms21082945] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
384 Hirth M, Gandla J, Höper C, Gaida MM, Agarwal N, Simonetti M, Demir A, Xie Y, Weiss C, Michalski CW, Hackert T, Ebert MP, Kuner R. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients. Gastroenterology 2020;159:665-681.e13. [PMID: 32330476 DOI: 10.1053/j.gastro.2020.04.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
385 Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CEM, Decker AR, Sastra SA, Palermo CF, Andrade LR, Sajjakulnukit P, Zhang L, Tolstyka ZP, Hirschhorn T, Lamb C, Liu T, Gu W, Seeley ES, Stone E, Georgiou G, Manor U, Iuga A, Wahl GM, Stockwell BR, Lyssiotis CA, Olive KP. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 2020;368:85-9. [PMID: 32241947 DOI: 10.1126/science.aaw9872] [Cited by in Crossref: 142] [Cited by in F6Publishing: 289] [Article Influence: 71.0] [Reference Citation Analysis]
386 Fanchon LM, Russell J, Pillarsetty N, O'Donoghue I, Gangangari K, Yu KH, Humm JL. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS One 2020;15:e0231745. [PMID: 32298392 DOI: 10.1371/journal.pone.0231745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
387 Resovi A, Borsotti P, Ceruti T, Passoni A, Zucchetti M, Berndt A, Riser BL, Taraboletti G, Belotti D. CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. Cells 2020;9:E952. [PMID: 32294968 DOI: 10.3390/cells9040952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
388 Wang CF, Shi XJ. Generation and application of patient-derived xenograft models in pancreatic cancer research. Chin Med J (Engl) 2019;132:2729-36. [PMID: 31725451 DOI: 10.1097/CM9.0000000000000524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
389 Muley H, Fadó R, Rodríguez-Rodríguez R, Casals N. Drug uptake-based chemoresistance in breast cancer treatment. Biochem Pharmacol 2020;177:113959. [PMID: 32272110 DOI: 10.1016/j.bcp.2020.113959] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
390 Mhaidly R, Mechta-grigoriou F. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies. Seminars in Immunology 2020;48:101417. [DOI: 10.1016/j.smim.2020.101417] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
391 Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB, Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-Curbelo D, Sridharan R, Heller DA, de Stanchina E, Stanger BZ, Sherr CJ, Lowe SW. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell 2020;181:424-441.e21. [PMID: 32234521 DOI: 10.1016/j.cell.2020.03.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 95] [Article Influence: 31.5] [Reference Citation Analysis]
392 Li T, Liu X, Xu B, Wu W, Zang Y, Li J, Wei L, Qian Y, Xu H, Xie M, Wang Q, Wang L. SKA1 regulates actin cytoskeleton remodelling via activating Cdc42 and influences the migration of pancreatic ductal adenocarcinoma cells. Cell Prolif 2020;53:e12799. [PMID: 32232899 DOI: 10.1111/cpr.12799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
393 Anbil S, Pigula M, Huang HC, Mallidi S, Broekgaarden M, Baglo Y, De Silva P, Simeone DM, Mino-Kenudson M, Maytin EV, Rizvi I, Hasan T. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Mol Cancer Ther 2020;19:1308-19. [PMID: 32220968 DOI: 10.1158/1535-7163.MCT-19-0791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
394 Sudo H, Tsuji AB, Sugyo A, Kurosawa G, Kurosawa Y, Alexander D, Tsuda H, Saga T, Higashi T. Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression. Int J Mol Sci 2020;21:E2304. [PMID: 32225110 DOI: 10.3390/ijms21072304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
395 Pausch TM, Aue E, Wirsik NM, Freire Valls A, Shen Y, Radhakrishnan P, Hackert T, Schneider M, Schmidt T. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Sci Rep 2020;10:5420. [PMID: 32214219 DOI: 10.1038/s41598-020-62416-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
396 Ben-Ami E, Perret R, Huang Y, Courgeon F, Gokhale PC, Laroche-Clary A, Eschle BK, Velasco V, Le Loarer F, Algeo MP, Purcell J, Demetri GD, Italiano A. LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. Cancers (Basel) 2020;12:E757. [PMID: 32210091 DOI: 10.3390/cancers12030757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
397 Ding L, Billadeau DD. Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer. Expert Opin Ther Targets 2020;24:417-26. [PMID: 32178549 DOI: 10.1080/14728222.2020.1743681] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
398 Storz P, Crawford HC. Carcinogenesis of Pancreatic Ductal Adenocarcinoma. Gastroenterology 2020;158:2072-81. [PMID: 32199881 DOI: 10.1053/j.gastro.2020.02.059] [Cited by in Crossref: 18] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
399 Steins A, van Mackelenbergh MG, van der Zalm AP, Klaassen R, Serrels B, Goris SG, Kocher HM, Waasdorp C, de Jong JH, Tekin C, Besselink MG, Busch OR, van de Vijver MJ, Verheij J, Dijk F, van Tienhoven G, Wilmink JW, Medema JP, van Laarhoven HW, Bijlsma MF. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. EMBO Rep 2020;21:e48780. [PMID: 32173982 DOI: 10.15252/embr.201948780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
400 Nabavizadeh A, Payen T, Iuga AC, Sagalovskiy IR, Desrouilleres D, Saharkhiz N, Palermo CF, Sastra SA, Oberstein PE, Rosario V, Kluger MD, Schrope BA, Chabot JA, Olive KP, Konofagou EE. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo. Theranostics 2020;10:4614-26. [PMID: 32292518 DOI: 10.7150/thno.37965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
401 Torphy RJ, Schulick RD, Zhu Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Mol Carcinog 2020;59:775-82. [PMID: 32166821 DOI: 10.1002/mc.23179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
402 Guo J, Zeng H, Chen Y. Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration. Mol Pharmaceutics 2020;17:1028-48. [DOI: 10.1021/acs.molpharmaceut.0c00014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
403 Salarian M, Ibhagui OY, Yang JJ. Molecular imaging of extracellular matrix proteins with targeted probes using magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2020;12:e1622. [PMID: 32126587 DOI: 10.1002/wnan.1622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
404 Ford K, Hanley CJ, Mellone M, Szyndralewiez C, Heitz F, Wiesel P, Wood O, Machado M, Lopez MA, Ganesan AP, Wang C, Chakravarthy A, Fenton TR, King EV, Vijayanand P, Ottensmeier CH, Al-Shamkhani A, Savelyeva N, Thomas GJ. NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. Cancer Res 2020;80:1846-60. [PMID: 32122909 DOI: 10.1158/0008-5472.CAN-19-3158] [Cited by in Crossref: 42] [Cited by in F6Publishing: 81] [Article Influence: 21.0] [Reference Citation Analysis]
405 Thomas SK, Lee J, Beatty GL. Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. EBioMedicine. 2020;53:102662. [PMID: 32139180 DOI: 10.1016/j.ebiom.2020.102662] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
406 Shi S, Liang C, Xu J, Meng Q, Hua J, Yang X, Ni Q, Yu X. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Annals of Surgery 2020;271:559-65. [DOI: 10.1097/sla.0000000000002998] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
407 Seynhaeve ALB, Amin M, Haemmerich D, van Rhoon GC, Ten Hagen TLM. Hyperthermia and smart drug delivery systems for solid tumor therapy. Adv Drug Deliv Rev 2020;163-164:125-44. [PMID: 32092379 DOI: 10.1016/j.addr.2020.02.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 30.5] [Reference Citation Analysis]
408 Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 2020; 12(2): 173-181 [PMID: 32104548 DOI: 10.4251/wjgo.v12.i2.173] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 59] [Article Influence: 36.0] [Reference Citation Analysis]
409 Lei Y, Chen T, Li Y, Shang M, Zhang Y, Jin Y, Yu Q, Guo F, Wang T. O-GlcNAcylation of PFKFB3 is required for tumor cell proliferation under hypoxia. Oncogenesis 2020;9:21. [PMID: 32060258 DOI: 10.1038/s41389-020-0208-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
410 Moore KM, Desai A, Delgado BL, Trabulo SMD, Reader C, Brown NF, Murray ER, Brentnall A, Howard P, Masterson L, Zammarchi F, Hartley JA, van Berkel PH, Marshall JF. Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics 2020;10:2930-42. [PMID: 32194845 DOI: 10.7150/thno.38702] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
411 Ma R, Yu Z, Cai Q, Li H, Dong Y, Oksman-Caldentey KM, Rischer H. Agrobacterium-Mediated Genetic Transformation of the Medicinal Plant Veratrum dahuricum. Plants (Basel) 2020;9:E191. [PMID: 32033134 DOI: 10.3390/plants9020191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
412 Dusetti N, Iovanna J. [Organoids from pancreatic ductal adenocarcinoma]. Med Sci (Paris) 2020;36:57-62. [PMID: 32014099 DOI: 10.1051/medsci/2019259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
413 Helms E, Onate MK, Sherman MH. Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment. Cancer Discov 2020;10:648-56. [PMID: 32014869 DOI: 10.1158/2159-8290.CD-19-1353] [Cited by in Crossref: 58] [Cited by in F6Publishing: 91] [Article Influence: 29.0] [Reference Citation Analysis]
414 Han X, Xu Y, Geranpayehvaghei M, Anderson GJ, Li Y, Nie G. Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors. Biomaterials 2020;232:119745. [DOI: 10.1016/j.biomaterials.2019.119745] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
415 Bradney MJ, Venis SM, Yang Y, Konieczny SF, Han B. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. Small 2020;16:e1905500. [PMID: 31997571 DOI: 10.1002/smll.201905500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
416 Xie Y, Hang Y, Wang Y, Sleightholm R, Prajapati DR, Bader J, Yu A, Tang W, Jaramillo L, Li J, Singh RK, Oupický D. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. ACS Nano 2020;14:255-71. [PMID: 31927946 DOI: 10.1021/acsnano.9b03978] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 25.5] [Reference Citation Analysis]
417 Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 2020;20:174-86. [PMID: 31980749 DOI: 10.1038/s41568-019-0238-1] [Cited by in Crossref: 447] [Cited by in F6Publishing: 824] [Article Influence: 223.5] [Reference Citation Analysis]
418 Sun J, Russell CC, Scarlett CJ, McCluskey A. Small molecule inhibitors in pancreatic cancer. RSC Med Chem 2020;11:164-83. [PMID: 33479626 DOI: 10.1039/c9md00447e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
419 Zheng J, Gao P. Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr Cancer Ther 2019;18:1534735419862352. [PMID: 31282197 DOI: 10.1177/1534735419862352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
420 Jeng KS, Chang CF, Lin SS. Sonic Hedgehog Signaling in Organogenesis, Tumors, and Tumor Microenvironments. Int J Mol Sci. 2020;21. [PMID: 31979397 DOI: 10.3390/ijms21030758] [Cited by in Crossref: 29] [Cited by in F6Publishing: 47] [Article Influence: 14.5] [Reference Citation Analysis]
421 Swayden M, Soubeyran P, Iovanna J. Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. Front Oncol 2019;9:1443. [PMID: 32038993 DOI: 10.3389/fonc.2019.01443] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
422 Dosch AR, Dai X, Reyzer ML, Mehra S, Srinivasan S, Willobee BA, Kwon D, Kashikar N, Caprioli R, Merchant NB, Nagathihalli NS. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Mol Cancer Res 2020;18:623-31. [PMID: 31949002 DOI: 10.1158/1541-7786.MCR-19-0741] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
423 Pothula SP, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression. Pancreatology 2020;20:409-18. [PMID: 31928917 DOI: 10.1016/j.pan.2020.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
424 Mardhian DF, Vrynas A, Storm G, Bansal R, Prakash J. FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor. Nanotheranostics 2020;4:26-39. [PMID: 31911892 DOI: 10.7150/ntno.38092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
425 Tolosa EJ, Fernández-Zapico ME. Targeting tumour microenvironment, a FAKtual challenge in pancreatic cancer. Gut 2020;69:1-2. [PMID: 31582402 DOI: 10.1136/gutjnl-2019-318962] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
426 Li ZX, Wu G, Jiang WJ, Li J, Wang YY, Ju XM, Yin YT. HOXB5 promotes malignant progression in pancreatic cancer via the miR-6732 pathway. Cell Cycle 2020;19:233-45. [PMID: 31876226 DOI: 10.1080/15384101.2019.1707456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
427 Hasselluhn MC, Klein L, Patzak MS, Buchholz SM, Ströbel P, Ellenrieder V, Maisonneuve P, Neesse A. Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer. Cells 2019;9:E58. [PMID: 31878349 DOI: 10.3390/cells9010058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
428 Sanchez A, Furberg H, Kuo F, Vuong L, Ged Y, Patil S, Ostrovnaya I, Petruzella S, Reising A, Patel P, Mano R, Coleman J, Russo P, Liu CH, Dannenberg AJ, Chan TA, Motzer R, Voss MH, Hakimi AA. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol 2020;21:283-93. [PMID: 31870811 DOI: 10.1016/S1470-2045(19)30797-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 13.7] [Reference Citation Analysis]
429 De Jesus-Acosta A, Sugar EA, O'Dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z, Zheng L, Begum A, Anders R, Maitra A, McAllister F, Rajeshkumar NV, Yabuuchi S, de Wilde RF, Batukbhai B, Sahin I, Laheru DA. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer. 2020;122:498-505. [PMID: 31857726 DOI: 10.1038/s41416-019-0683-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
430 Vernucci E, Abrego J, Gunda V, Shukla SK, Dasgupta A, Rai V, Chaika N, Buettner K, Illies A, Yu F, Lazenby AJ, Swanson BJ, Singh PK. Metabolic Alterations in Pancreatic Cancer Progression. Cancers (Basel) 2019;12:E2. [PMID: 31861288 DOI: 10.3390/cancers12010002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
431 Thomas OS, Weber W. Overcoming Physiological Barriers to Nanoparticle Delivery-Are We There Yet? Front Bioeng Biotechnol 2019;7:415. [PMID: 31921819 DOI: 10.3389/fbioe.2019.00415] [Cited by in Crossref: 34] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
432 Leenhardt R, Camus M, Mestas JL, Jeljeli M, Abou Ali E, Chouzenoux S, Bordacahar B, Nicco C, Batteux F, Lafon C, Prat F. Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment. Sci Rep 2019;9:18916. [PMID: 31831785 DOI: 10.1038/s41598-019-55388-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
433 Payen T, Oberstein PE, Saharkhiz N, Palermo CF, Sastra SA, Han Y, Nabavizadeh A, Sagalovskiy IR, Orelli B, Rosario V, Desrouilleres D, Remotti H, Kluger MD, Schrope BA, Chabot JA, Iuga AC, Konofagou EE, Olive KP. Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response. Clin Cancer Res 2020;26:1297-308. [PMID: 31831559 DOI: 10.1158/1078-0432.CCR-18-3669] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
434 Katayama MLH, Vieira RADC, Andrade VP, Roela RA, Lima LGCA, Kerr LM, Campos AP, Pereira CAB, Serio PAMP, Encinas G, Maistro S, Petroni MAL, Brentani MM, Folgueira MAAK. Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Cells 2019;8:E1566. [PMID: 31817155 DOI: 10.3390/cells8121566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
435 Ding J, Chen J, Gao L, Jiang Z, Zhang Y, Li M, Xiao Q, Lee SS, Chen X. Engineered nanomedicines with enhanced tumor penetration. Nano Today 2019;29:100800. [DOI: 10.1016/j.nantod.2019.100800] [Cited by in Crossref: 129] [Cited by in F6Publishing: 79] [Article Influence: 43.0] [Reference Citation Analysis]
436 Erlangga Z, Wolff K, Poth T, Peltzer A, Nahnsen S, Spielberg S, Timrott K, Woller N, Kühnel F, Manns MP, Saborowski A, Vogel A, Saborowski M. Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers (Basel) 2019;11:E1904. [PMID: 31795490 DOI: 10.3390/cancers11121904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
437 Niknafs N, Zhong Y, Moral JA, Zhang L, Shao MX, Lo A, Makohon-Moore A, Iacobuzio-Donahue CA, Karchin R. Characterization of genetic subclonal evolution in pancreatic cancer mouse models. Nat Commun 2019;10:5435. [PMID: 31780749 DOI: 10.1038/s41467-019-13100-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
438 Xu Y, Song S, Wang Z, Ajani JA. The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective.Cell Commun Signal. 2019;17:157. [PMID: 31775795 DOI: 10.1186/s12964-019-0479-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
439 Xie P, Gao M, Wang C, Zhang J, Noel P, Yang C, Von Hoff D, Han H, Zhang MQ, Lin W. SuperCT: a supervised-learning framework for enhanced characterization of single-cell transcriptomic profiles. Nucleic Acids Res. 2019;47:e48. [PMID: 30799483 DOI: 10.1093/nar/gkz116] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
440 Batista S, Gregório AC, Hanada Otake A, Couto N, Costa-Silva B. The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. J Oncol 2019;2019:6240505. [PMID: 31885581 DOI: 10.1155/2019/6240505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
441 McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.Pancreatology. 2020;20:101-109. [PMID: 31787526 DOI: 10.1016/j.pan.2019.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
442 Ariston Gabriel AN, Jiao Q, Yvette U, Yang X, Al-Ameri SA, Du L, Wang YS, Wang C. Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance. Pancreatology 2020;20:79-88. [PMID: 31780287 DOI: 10.1016/j.pan.2019.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
443 Li X, Yang Z, Xu S, Wang Z, Jin P, Yang X, Zhang Z, Wang Y, Wei X, Fang T, Gao Q. Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation. Dis Markers 2019;2019:7275289. [PMID: 31827640 DOI: 10.1155/2019/7275289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
444 Yeow YL, Kotamraju VR, Wang X, Chopra M, Azme N, Wu J, Schoep TD, Delaney DS, Feindel K, Li J, Kennedy KM, Allen WM, Kennedy BF, Larma I, Sampson DD, Mahakian LM, Fite BZ, Zhang H, Friman T, Mann AP, Aziz FA, Kumarasinghe MP, Johansson M, Ee HC, Yeoh G, Mou L, Ferrara KW, Billiran H, Ganss R, Ruoslahti E, Hamzah J. Immune-mediated ECM depletion improves tumour perfusion and payload delivery. EMBO Mol Med 2019;11:e10923. [PMID: 31709774 DOI: 10.15252/emmm.201910923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
445 Chen Z, Li Y, Airan R, Han Z, Xu J, Chan KWY, Xu Y, Bulte JWM, van Zijl PCM, McMahon MT, Zhou S, Liu G. CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. Quant Imaging Med Surg 2019;9:1579-91. [PMID: 31667143 DOI: 10.21037/qims.2019.06.10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
446 Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel B, Kwak C, Choudhary GS, Gordon-Mitchell S, Aluri S, Bhattacharyya S, Sahu S, Bhagat P, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Guerrero PA, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D, Maitra A, Verma A. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife 2019;8:e50663. [PMID: 31663852 DOI: 10.7554/eLife.50663] [Cited by in Crossref: 38] [Cited by in F6Publishing: 54] [Article Influence: 12.7] [Reference Citation Analysis]
447 Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, Cox TR, Timpson P. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Trends in Cancer 2019;5:724-41. [DOI: 10.1016/j.trecan.2019.09.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 24.0] [Reference Citation Analysis]
448 Müller D, Shin S, Goullet de Rugy T, Samain R, Baer R, Strehaiano M, Masvidal-Sanz L, Guillermet-Guibert J, Jean C, Tsukumo Y, Sonenberg N, Marion F, Guilbaud N, Hoffmann JS, Larsson O, Bousquet C, Pyronnet S, Martineau Y. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. JCI Insight 2019;4:121951. [PMID: 31672935 DOI: 10.1172/jci.insight.121951] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
449 Ichimaru Y, Sano M, Kajiwara I, Tobe T, Yoshioka H, Hayashi K, Ijichi H, Miyairi S. Indirubin 3'-Oxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways. Transl Oncol 2019;12:1574-82. [PMID: 31671317 DOI: 10.1016/j.tranon.2019.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
450 Liu Y, Huo Y, Yao L, Xu Y, Meng F, Li H, Sun K, Zhou G, Kohane DS, Tao K. Transcytosis of Nanomedicine for Tumor Penetration. Nano Lett 2019;19:8010-20. [PMID: 31639306 DOI: 10.1021/acs.nanolett.9b03211] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
451 An Y, Liu F, Chen Y, Yang Q. Crosstalk between cancer-associated fibroblasts and immune cells in cancer. J Cell Mol Med 2020;24:13-24. [PMID: 31642585 DOI: 10.1111/jcmm.14745] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
452 Zinger A, Koren L, Adir O, Poley M, Alyan M, Yaari Z, Noor N, Krinsky N, Simon A, Gibori H, Krayem M, Mumblat Y, Kasten S, Ofir S, Fridman E, Milman N, Lübtow MM, Liba L, Shklover J, Shainsky-Roitman J, Binenbaum Y, Hershkovitz D, Gil Z, Dvir T, Luxenhofer R, Satchi-Fainaro R, Schroeder A. Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors. ACS Nano 2019;13:11008-21. [PMID: 31503443 DOI: 10.1021/acsnano.9b02395] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 38.0] [Reference Citation Analysis]
453 Lafaro KJ, Melstrom LG. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. Am J Pathol 2019;189:44-57. [PMID: 30558722 DOI: 10.1016/j.ajpath.2018.09.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
454 Dominiak A, Nowicki T, Łacheta D, Nowicka G. Cancer-associated fibroblasts as a potential target in oncology therapy. Postepy Hig Med Dosw 2019;73:536-49. [DOI: 10.5604/01.3001.0013.5379] [Reference Citation Analysis]
455 Zhou L, Husted H, Moore T, Lu M, Deng D, Liu Y, Ramachandran V, Arumugam T, Niehrs C, Wang H, Chiao P, Ling J, Curran MA, Maitra A, Hung MC, Lee JE, Logsdon CD, Hwang RF. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Sci Transl Med 2018;10:eaat3487. [PMID: 30355799 DOI: 10.1126/scitranslmed.aat3487] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
456 Ramu I, Buchholz SM, Patzak MS, Goetze RG, Singh SK, Richards FM, Jodrell DI, Sipos B, Ströbel P, Ellenrieder V, Hessmann E, Neesse A. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer. EBioMedicine 2019;48:161-8. [PMID: 31597597 DOI: 10.1016/j.ebiom.2019.09.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
457 Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, Zheng W, Lu Y, Zhang W, Bei Y, Shen P. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer 2019;121:837-45. [PMID: 31570753 DOI: 10.1038/s41416-019-0578-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 51] [Article Influence: 9.7] [Reference Citation Analysis]
458 Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ. CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. Cell Rep 2018;23:1448-60. [PMID: 29719257 DOI: 10.1016/j.celrep.2018.03.131] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 27.3] [Reference Citation Analysis]
459 Zhu Y, Yu F, Tan Y, Yuan H, Hu F. Strategies of targeting pathological stroma for enhanced antitumor therapies. Pharmacological Research 2019;148:104401. [DOI: 10.1016/j.phrs.2019.104401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
460 Moosavian SA, Bianconi V, Pirro M, Sahebkar A. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Semin Cancer Biol 2021;69:337-48. [PMID: 31585213 DOI: 10.1016/j.semcancer.2019.09.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
461 Zhu Y, Yu F, Tan Y, Hong Y, Meng T, Liu Y, Dai S, Qiu G, Yuan H, Hu F. Reversing activity of cancer associated fibroblast for staged glycolipid micelles against internal breast tumor cells. Theranostics 2019;9:6764-79. [PMID: 31660067 DOI: 10.7150/thno.36334] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
462 Kramer B, Haan L, Vermeer M, Olivier T, Hankemeier T, Vulto P, Joore J, Lanz HL. Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins. Int J Mol Sci 2019;20:E4647. [PMID: 31546820 DOI: 10.3390/ijms20184647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
463 Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
464 Upadhrasta S, Zheng L. Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune "Defects" in the Tumor Microenvironment. J Clin Med. 2019;8. [PMID: 31527414 DOI: 10.3390/jcm8091472] [Cited by in Crossref: 20] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
465 Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. Int J Mol Sci 2019;20:E4504. [PMID: 31514451 DOI: 10.3390/ijms20184504] [Cited by in Crossref: 64] [Cited by in F6Publishing: 124] [Article Influence: 21.3] [Reference Citation Analysis]
466 Chen J, Weihs D, Vermolen FJ. Computational modeling of therapy on pancreatic cancer in its early stages. Biomech Model Mechanobiol 2020;19:427-44. [PMID: 31501963 DOI: 10.1007/s10237-019-01219-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
467 Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers (Basel) 2019;11:E1321. [PMID: 31500168 DOI: 10.3390/cancers11091321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
468 Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, Hwang CI, Öhlund D, Chio IIC, Baker LA, Filippini D, Wright K, Bapiro TE, Huang P, Smith P, Yu KH, Jodrell DI, Park Y, Tuveson DA. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clin Cancer Res 2019;25:6742-55. [PMID: 31492749 DOI: 10.1158/1078-0432.CCR-19-1398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
469 Webster JD, Santagostino SF, Foreman O. Applications and considerations for the use of genetically engineered mouse models in drug development. Cell Tissue Res 2020;380:325-40. [DOI: 10.1007/s00441-019-03101-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
470 Fong CYK, Burke E, Cunningham D, Starling N. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Gastroenterol Res Pract 2019;2019:7135437. [PMID: 31582971 DOI: 10.1155/2019/7135437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
471 Tian C, Clauser KR, Öhlund D, Rickelt S, Huang Y, Gupta M, Mani DR, Carr SA, Tuveson DA, Hynes RO. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A 2019;116:19609-18. [PMID: 31484774 DOI: 10.1073/pnas.1908626116] [Cited by in Crossref: 69] [Cited by in F6Publishing: 117] [Article Influence: 23.0] [Reference Citation Analysis]
472 Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Vander Heiden MG, Lauffenburger DA, Hemann MT. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Res 2019;79:5723-33. [PMID: 31484670 DOI: 10.1158/0008-5472.CAN-19-0960] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
473 Hernandez-Unzueta I, Benedicto A, Romayor I, Herrero A, Sanz E, Arteta B, Olaso E, Márquez J. Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance. Pancreas 2019;48:555-67. [PMID: 30946238 DOI: 10.1097/MPA.0000000000001277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
474 Begum A, McMillan RH, Chang YT, Penchev VR, Rajeshkumar NV, Maitra A, Goggins MG, Eshelman JR, Wolfgang CL, Rasheed ZA, Matsui W. Direct Interactions With Cancer-Associated Fibroblasts Lead to Enhanced Pancreatic Cancer Stem Cell Function. Pancreas 2019;48:329-34. [PMID: 30747824 DOI: 10.1097/MPA.0000000000001249] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
475 Nguyen DT, Lee E, Alimperti S, Norgard RJ, Wong A, Lee JJ, Eyckmans J, Stanger BZ, Chen CS. A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling. Sci Adv 2019;5:eaav6789. [PMID: 31489365 DOI: 10.1126/sciadv.aav6789] [Cited by in Crossref: 44] [Cited by in F6Publishing: 52] [Article Influence: 14.7] [Reference Citation Analysis]
476 Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol 2019;12:86. [PMID: 31462327 DOI: 10.1186/s13045-019-0770-1] [Cited by in Crossref: 177] [Cited by in F6Publishing: 271] [Article Influence: 59.0] [Reference Citation Analysis]
477 Gioeli D, Snow CJ, Simmers MB, Hoang SA, Figler RA, Allende JA, Roller DG, Parsons JT, Wulfkuhle JD, Petricoin EF, Bauer TW, Wamhoff BR. Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells. Lab Chip 2019;19:1193-204. [PMID: 30839006 DOI: 10.1039/c8lc00755a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
478 Filippini D, Agosto S, Delfino P, Simbolo M, Piro G, Rusev B, Veghini L, Cantù C, Lupo F, Ugel S, De Sanctis F, Bronte V, Milella M, Tortora G, Scarpa A, Carbone C, Corbo V. Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. Sci Rep 2019;9:12286. [PMID: 31439856 DOI: 10.1038/s41598-019-48663-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
479 Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W, Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P; Australian Pancreatic Genome Initiative (APGI). CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat Commun 2019;10:3637. [PMID: 31406163 DOI: 10.1038/s41467-019-10968-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 95] [Article Influence: 23.7] [Reference Citation Analysis]
480 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 117] [Article Influence: 24.7] [Reference Citation Analysis]
481 Koba R, Fujita H, Nishibori M, Saeki K, Nagayoshi K, Sadakari Y, Nagai S, Sekizawa O, Nitta K, Manabe T, Ueki T, Ishida T, Oda Y, Nakamura M. Quantitative evaluation of the intratumoral distribution of platinum in oxaliplatin‐treated rectal cancer: In situ visualization of platinum via synchrotron radiation X‐ray fluorescence spectrometry. Int J Cancer 2020;146:2498-509. [DOI: 10.1002/ijc.32592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
482 Chakraborty S, Banerjee S, Raina M, Haldar S. Force-Directed “Mechanointeractome” of Talin–Integrin. Biochemistry 2019;58:4677-95. [DOI: 10.1021/acs.biochem.9b00442] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
483 Tandon M, Coudriet GM, Criscimanna A, Socorro M, Eliliwi M, Singhi AD, Cruz-Monserrate Z, Bailey P, Lotze MT, Zeh H, Hu J, Goffin V, Gittes GK, Biankin AV, Esni F. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Cancer Res 2019;79:5316-27. [PMID: 31395607 DOI: 10.1158/0008-5472.CAN-18-3064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
484 Adamska A, Domenichini A, Capone E, Damiani V, Akkaya BG, Linton KJ, Di Sebastiano P, Chen X, Keeton AB, Ramirez-Alcantara V, Maxuitenko Y, Piazza GA, De Laurenzi V, Sala G, Falasca M. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. J Exp Clin Cancer Res 2019;38:312. [PMID: 31378204 DOI: 10.1186/s13046-019-1308-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
485 Farran B, Nagaraju GP. The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets. Cytokine & Growth Factor Reviews 2019;48:11-23. [DOI: 10.1016/j.cytogfr.2019.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
486 Chan TS, Shaked Y, Tsai KK. Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers. Front Oncol 2019;9:688. [PMID: 31417869 DOI: 10.3389/fonc.2019.00688] [Cited by in Crossref: 37] [Cited by in F6Publishing: 55] [Article Influence: 12.3] [Reference Citation Analysis]
487 Wang J, Chan DKW, Sen A, Ma WW, Straubinger RM. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. Mol Cancer Ther 2019;18:2074-84. [PMID: 31363010 DOI: 10.1158/1535-7163.MCT-18-0354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
488 Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J Pathol 2019;249:332-42. [PMID: 31259422 DOI: 10.1002/path.5320] [Cited by in Crossref: 23] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
489 Xiao Y, Zhang H, Ma Q, Huang R, Lu J, Liang X, Liu X, Zhang Z, Yu L, Pang J, Zhou L, Liu T, Wu H, Liang Z. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Cancer Lett 2019;462:51-60. [PMID: 31352078 DOI: 10.1016/j.canlet.2019.07.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
490 Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, Worthley DL. Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol 2019;16:282-95. [PMID: 30778141 DOI: 10.1038/s41575-019-0115-0] [Cited by in Crossref: 170] [Cited by in F6Publishing: 179] [Article Influence: 56.7] [Reference Citation Analysis]
491 Liu Z, Zhang L, Tian Z, Kong C, Liu C, Liu H, Yuan F, Kong W, Qian F. Paclitaxel and Itraconazole Co‐Encapsulated Micelle Prolongs the Survival of Spontaneous LSL‐Kras G12D/+ , LSL‐Trp53 R172H/+ , Pdx‐1‐Cre Genetically Engineered Mouse Model of Pancreatic Cancer. Adv Therap 2019;2:1900032. [DOI: 10.1002/adtp.201900032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
492 Hara T, Verma IM. Modeling Gliomas Using Two Recombinases. Cancer Res 2019;79:3983-91. [PMID: 31315836 DOI: 10.1158/0008-5472.CAN-19-0717] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
493 Meier-Hubberten JC, Sanderson MP. Establishment and Analysis of a 3D Co-Culture Spheroid Model of Pancreatic Adenocarcinoma for Application in Drug Discovery. Methods Mol Biol 2019;1953:163-79. [PMID: 30912022 DOI: 10.1007/978-1-4939-9145-7_11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
494 Wang B, Shen C, Li Y, Zhang T, Huang H, Ren J, Hu Z, Xu J, Xu B. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling. Onco Targets Ther 2019;12:5751-65. [PMID: 31410021 DOI: 10.2147/OTT.S208924] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
495 Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333-348. [PMID: 29717230 DOI: 10.1038/s41575-018-0005-x] [Cited by in Crossref: 442] [Cited by in F6Publishing: 430] [Article Influence: 147.3] [Reference Citation Analysis]
496 Hossen MN, Rao G, Dey A, Robertson JD, Bhattacharya R, Mukherjee P. Gold Nanoparticle Transforms Activated Cancer-Associated Fibroblasts to Quiescence. ACS Appl Mater Interfaces 2019;11:26060-8. [PMID: 31117437 DOI: 10.1021/acsami.9b03313] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
497 Gieniec KA, Butler LM, Worthley DL, Woods SL. Cancer-associated fibroblasts-heroes or villains? Br J Cancer 2019;121:293-302. [PMID: 31289350 DOI: 10.1038/s41416-019-0509-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 87] [Article Influence: 20.3] [Reference Citation Analysis]
498 Anderson RL, Balasas T, Callaghan J, Coombes RC, Evans J, Hall JA, Kinrade S, Jones D, Jones PS, Jones R, Marshall JF, Panico MB, Shaw JA, Steeg PS, Sullivan M, Tong W, Westwell AD, Ritchie JWA; Cancer Research UK and Cancer Therapeutics CRC Australia Metastasis Working Group. A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol. 2019;16:185-204. [PMID: 30514977 DOI: 10.1038/s41571-018-0134-8] [Cited by in Crossref: 87] [Cited by in F6Publishing: 121] [Article Influence: 29.0] [Reference Citation Analysis]
499 Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, Yeo CJ, Winter JM, Olive KP, Golan T, Pishvaian MJ, Ogilvie D, James DI, Jordan AM, Brody JR. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Res 2019;79:4491-502. [PMID: 31273064 DOI: 10.1158/0008-5472.CAN-18-3645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
500 Martinez VG, Park D, Acton SE. Immunotherapy: breaching the barriers for cancer treatment. Philos Trans R Soc Lond B Biol Sci 2019;374:20180214. [PMID: 31431180 DOI: 10.1098/rstb.2018.0214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
501 Chapouly C, Guimbal S, Hollier PL, Renault MA. Role of Hedgehog Signaling in Vasculature Development, Differentiation, and Maintenance. Int J Mol Sci. 2019;20. [PMID: 31238510 DOI: 10.3390/ijms20123076] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
502 Li J, Hu K, Zhang Y, Zhang Z, Li H. Highly sensitive detection of Smoothened based on the drug binding and rolling cycle amplification. Anal Bioanal Chem 2019;411:5721-7. [PMID: 31214754 DOI: 10.1007/s00216-019-01950-8] [Reference Citation Analysis]
503 Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019;9:1102-1123. [PMID: 31197017 DOI: 10.1158/2159-8290.cd-19-0094] [Cited by in Crossref: 308] [Cited by in F6Publishing: 447] [Article Influence: 102.7] [Reference Citation Analysis]
504 Goetze RG, Buchholz SM, Ou N, Zhang Q, Patil S, Schirmer M, Singh SK, Ellenrieder V, Hessmann E, Lu QB, Neesse A. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Cells 2019;8:E563. [PMID: 31181844 DOI: 10.3390/cells8060563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
505 Chowdury MA, Heileman KL, Moore TA, Young EWK. Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. SLAS Technol 2019;24:457-76. [PMID: 31173533 DOI: 10.1177/2472630319846878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
506 Underwood PW, Trevino JG. A deeper understanding of the tumor microenvironment in pancreatic cancer: the key to developing effective immunotherapies. Ann Transl Med 2019;7:162. [PMID: 31168443 DOI: 10.21037/atm.2019.03.14] [Reference Citation Analysis]
507 D'Agosto S, Andreani S, Scarpa A, Corbo V. Preclinical Modelling of PDA: Is Organoid the New Black? Int J Mol Sci 2019;20:E2766. [PMID: 31195689 DOI: 10.3390/ijms20112766] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
508 Maloney E, DuFort CC, Provenzano PP, Farr N, Carlson MA, Vohra R, Park J, Hingorani SR, Lee D. Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2019;11. [PMID: 31167451 DOI: 10.3390/cancers11060772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
509 Bott AJ, Maimouni S, Zong WX. The Pleiotropic Effects of Glutamine Metabolism in Cancer. Cancers (Basel) 2019;11:E770. [PMID: 31167399 DOI: 10.3390/cancers11060770] [Cited by in Crossref: 38] [Cited by in F6Publishing: 56] [Article Influence: 12.7] [Reference Citation Analysis]
510 Gulzar A, Xu J, Wang C, He F, Yang D, Gai S, Yang P, Lin J, Jin D, Xing B. Tumour microenvironment responsive nanoconstructs for cancer theranostic. Nano Today 2019;26:16-56. [DOI: 10.1016/j.nantod.2019.03.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
511 Maurer C, Holmstrom SR, He J, Laise P, Su T, Ahmed A, Hibshoosh H, Chabot JA, Oberstein PE, Sepulveda AR, Genkinger JM, Zhang J, Iuga AC, Bansal M, Califano A, Olive KP. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut 2019;68:1034-43. [PMID: 30658994 DOI: 10.1136/gutjnl-2018-317706] [Cited by in Crossref: 96] [Cited by in F6Publishing: 69] [Article Influence: 32.0] [Reference Citation Analysis]
512 Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, Arora KS, Rajurkar M, Horwitz E, Neyaz A, Tai E, Magnus NKC, Vo KD, Yashaswini CN, Marangoni F, Boukhali M, Fatherree JP, Damon LJ, Xega K, Desai R, Choz M, Bersani F, Langenbucher A, Thapar V, Morris R, Wellner UF, Schilling O, Lawrence MS, Liss AS, Rivera MN, Deshpande V, Benes CH, Maheswaran S, Haber DA, Fernandez-Del-Castillo C, Ferrone CR, Haas W, Aryee MJ, Ting DT. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell 2019;178:160-175.e27. [PMID: 31155233 DOI: 10.1016/j.cell.2019.05.012] [Cited by in Crossref: 143] [Cited by in F6Publishing: 209] [Article Influence: 47.7] [Reference Citation Analysis]
513 El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E. Pharmacogenetics of treatments for pancreatic cancer. Expert Opin Drug Metab Toxicol 2019;15:437-47. [PMID: 31100206 DOI: 10.1080/17425255.2019.1620731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
514 Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366-381. [PMID: 29651130 DOI: 10.1038/s41571-018-0007-1] [Cited by in Crossref: 308] [Cited by in F6Publishing: 392] [Article Influence: 102.7] [Reference Citation Analysis]
515 Liu H, Kiseleva AA, Golemis EA. Ciliary signalling in cancer. Nat Rev Cancer. 2018;18:511-524. [PMID: 29802351 DOI: 10.1038/s41568-018-0023-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 20.0] [Reference Citation Analysis]
516 Tsai KK, Chan TS, Shaked Y. Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. J Clin Med 2019;8:E702. [PMID: 31108941 DOI: 10.3390/jcm8050702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
517 Lu Y, Xu D, Peng J, Luo Z, Chen C, Chen Y, Chen H, Zheng M, Yin P, Wang Z. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. EBioMedicine 2019;44:403-18. [PMID: 31103629 DOI: 10.1016/j.ebiom.2019.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
518 Elwakeel E, Brüne B, Weigert A. PGE2 in fibrosis and cancer: Insights into fibroblast activation. Prostaglandins Other Lipid Mediat 2019;143:106339. [PMID: 31100473 DOI: 10.1016/j.prostaglandins.2019.106339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
519 Wong CW, Han HW, Tien YW, Hsu SH. Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment. Biomaterials 2019;213:119202. [PMID: 31132644 DOI: 10.1016/j.biomaterials.2019.05.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
520 Oh S, Park JT. Zebrafish model of KRAS-initiated pancreatic endocrine tumor. Anim Cells Syst (Seoul) 2019;23:209-18. [PMID: 31231585 DOI: 10.1080/19768354.2019.1610058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
521 Chen YT, Chen FW, Chang TH, Wang TW, Hsu TP, Chi JY, Hsiao YW, Li CF, Wang JM. Hepatoma-derived growth factor supports the antiapoptosis and profibrosis of pancreatic stellate cells. Cancer Lett 2019;457:180-90. [PMID: 31078734 DOI: 10.1016/j.canlet.2019.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
522 Saini F, Argent RH, Grabowska AM. Sonic Hedgehog Ligand: A Role in Formation of a Mesenchymal Niche in Human Pancreatic Ductal Adenocarcinoma. Cells 2019;8:E424. [PMID: 31072042 DOI: 10.3390/cells8050424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
523 Leal AS, Misek SA, Lisabeth EM, Neubig RR, Liby KT. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Sci Rep 2019;9:7072. [PMID: 31068602 DOI: 10.1038/s41598-019-43430-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
524 Yoshida GJ, Azuma A, Miura Y, Orimo A. Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. Int J Mol Sci 2019;20:E2256. [PMID: 31067787 DOI: 10.3390/ijms20092256] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 24.0] [Reference Citation Analysis]
525 Cortes JE, Gutzmer R, Kieran MW, Solomon JA. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev 2019;76:41-50. [PMID: 31125907 DOI: 10.1016/j.ctrv.2019.04.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
526 Kim S, Kim Y, Kong J, Kim E, Choi JH, Yuk HD, Lee H, Kim HR, Lee KH, Kang M, Roe JS, Moon KC, Kim S, Ku JH, Shin K. Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. Elife 2019;8:e43024. [PMID: 31036156 DOI: 10.7554/eLife.43024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
527 Hussain S, Singh A, Nazir SU, Tulsyan S, Khan A, Kumar R, Bashir N, Tanwar P, Mehrotra R. Cancer drug resistance: A fleet to conquer. J Cell Biochem 2019;120:14213-25. [PMID: 31037763 DOI: 10.1002/jcb.28782] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
528 Xie H, Paradise BD, Ma WW, Fernandez-Zapico ME. Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer. Cells 2019;8:E394. [PMID: 31035664 DOI: 10.3390/cells8050394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
529 Katoh M. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. Clin Sci (Lond). 2019;133:953-970. [PMID: 31036756 DOI: 10.1042/cs20180845] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 8.7] [Reference Citation Analysis]
530 Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer 2019;7:115. [PMID: 31036082 DOI: 10.1186/s40425-019-0573-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 46] [Article Influence: 10.7] [Reference Citation Analysis]
531 Awaji M, Futakuchi M, Heavican T, Iqbal J, Singh RK. Cancer-Associated Fibroblasts Enhance Survival and Progression of the Aggressive Pancreatic Tumor Via FGF-2 and CXCL8. Cancer Microenviron 2019;12:37-46. [PMID: 31025289 DOI: 10.1007/s12307-019-00223-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
532 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
533 Houthuijzen JM, Jonkers J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. Cancer Metastasis Rev 2018;37:577-97. [PMID: 30465162 DOI: 10.1007/s10555-018-9768-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 19.7] [Reference Citation Analysis]
534 Vitale I, Manic G, Galassi C, Galluzzi L. Stress responses in stromal cells and tumor homeostasis. Pharmacol Ther 2019;200:55-68. [PMID: 30998941 DOI: 10.1016/j.pharmthera.2019.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
535 Sullivan MR, Danai LV, Lewis CA, Chan SH, Gui DY, Kunchok T, Dennstedt EA, Vander Heiden MG, Muir A. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife 2019;8:e44235. [PMID: 30990168 DOI: 10.7554/eLife.44235] [Cited by in Crossref: 133] [Cited by in F6Publishing: 152] [Article Influence: 44.3] [Reference Citation Analysis]
536 Xu Y, Xu H, Li M, Wu H, Guo Y, Chen J, Shan J, Chen X, Shen J, Ma Q, Liu J, Wang M, Zhao W, Hong J, Qi Y, Yao C, Zhang Q, Yang Z, Qian C, Li J. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. Cancer Lett 2019;454:78-89. [PMID: 30980868 DOI: 10.1016/j.canlet.2019.03.049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
537 Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, Yallapu MM, Stiles ZE, Alabkaa A, Yue J, Ganju A, Behrman S, Jaggi M, Chauhan SC. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials 2019;208:83-97. [PMID: 30999154 DOI: 10.1016/j.biomaterials.2019.04.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
538 Bulin AL, Broekgaarden M, Simeone D, Hasan T. Low dose photodynamic therapy harmonizes with radiation therapy to induce beneficial effects on pancreatic heterocellular spheroids. Oncotarget 2019;10:2625-43. [PMID: 31080554 DOI: 10.18632/oncotarget.26780] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
539 Koom WS, Mori S, Furuich W, Yamada S. Beam direction arrangement using a superconducting rotating gantry in carbon ion treatment for pancreatic cancer. Br J Radiol 2019;92:20190101. [PMID: 30943057 DOI: 10.1259/bjr.20190101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
540 Moutinho-Ribeiro P, Liberal R, Macedo G. Endoscopic ultrasound in pancreatic cancer treatment: Facts and hopes. Clin Res Hepatol Gastroenterol 2019;43:513-21. [PMID: 30935904 DOI: 10.1016/j.clinre.2019.02.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
541 Goehrig D, Nigri J, Samain R, Wu Z, Cappello P, Gabiane G, Zhang X, Zhao Y, Kim IS, Chanal M, Curto R, Hervieu V, de La Fouchardière C, Novelli F, Milani P, Tomasini R, Bousquet C, Bertolino P, Hennino A. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Gut 2019;68:693-707. [PMID: 30415234 DOI: 10.1136/gutjnl-2018-317570] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 13.7] [Reference Citation Analysis]
542 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
543 D'Errico G, Alonso-Nocelo M, Vallespinos M, Hermann PC, Alcalá S, García CP, Martin-Hijano L, Valle S, Earl J, Cassiano C, Lombardia L, Feliu J, Monti MC, Seufferlein T, García-Bermejo L, Martinelli P, Carrato A, Sainz B Jr. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Oncogene 2019;38:5469-85. [PMID: 30936462 DOI: 10.1038/s41388-019-0803-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 7.7] [Reference Citation Analysis]
544 Fang L, Kong SS, Zhong LK, Wang CM, Liu YJ, Ding HY, Sun J, Zhang YW, Li FZ, Huang P. Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen. Acta Pharmacol Sin 2019;40:539-45. [PMID: 29921887 DOI: 10.1038/s41401-018-0038-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
545 Barilla RM, Diskin B, Caso RC, Lee KB, Mohan N, Buttar C, Adam S, Sekendiz Z, Wang J, Salas RD, Cassini MF, Karlen J, Sundberg B, Akbar H, Levchenko D, Gakhal I, Gutierrez J, Wang W, Hundeyin M, Torres-Hernandez A, Leinwand J, Kurz E, Rossi JAK, Mishra A, Liria M, Sanchez G, Panta J, Loke P, Aykut B, Miller G. Specialized dendritic cells induce tumor-promoting IL-10+IL-17+ FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma. Nat Commun 2019;10:1424. [PMID: 30926808 DOI: 10.1038/s41467-019-09416-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
546 Tariq NU, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res 2019;11:2623-42. [PMID: 31015767 DOI: 10.2147/CMAR.S157092] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
547 Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers (Basel). 2019;11. [PMID: 30909618 DOI: 10.3390/cancers11030416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 8.7] [Reference Citation Analysis]
548 Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers (Basel) 2019;11:E416. [PMID: 30909618 DOI: 10.3390/cancers11030416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
549 Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers (Basel) 2019;11:E416. [PMID: 30909618 DOI: 10.3390/cancers11030416] [Reference Citation Analysis]
550 Curran T. Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer. Open Biol 2018;8:180098. [PMID: 30068568 DOI: 10.1098/rsob.180098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
551 Annese T, Tamma R, Ruggieri S, Ribatti D. Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. Cancers (Basel) 2019;11:E381. [PMID: 30889903 DOI: 10.3390/cancers11030381] [Cited by in Crossref: 18] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
552 Wang-Gillam A. Targeting Stroma: A Tale of Caution. J Clin Oncol. 2019;37:1041-1043. [PMID: 30860950 DOI: 10.1200/jco.19.00056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
553 Porcelli L, Iacobazzi RM, Di Fonte R, Serratì S, Intini A, Solimando AG, Brunetti O, Calabrese A, Leonetti F, Azzariti A, Silvestris N. CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers (Basel) 2019;11:E330. [PMID: 30866547 DOI: 10.3390/cancers11030330] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 15.7] [Reference Citation Analysis]
554 Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, O'Hare T, Deininger MW, Singh SK, Konieczny SF, Weiss S, Fishel ML, Gunning PT. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem 2019;62:2651-65. [PMID: 30776234 DOI: 10.1021/acs.jmedchem.8b01957] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
555 Auciello FR, Bulusu V, Oon C, Tait-Mulder J, Berry M, Bhattacharyya S, Tumanov S, Allen-Petersen BL, Link J, Kendsersky ND, Vringer E, Schug M, Novo D, Hwang RF, Evans RM, Nixon C, Dorrell C, Morton JP, Norman JC, Sears RC, Kamphorst JJ, Sherman MH. A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression. Cancer Discov 2019;9:617-27. [PMID: 30837243 DOI: 10.1158/2159-8290.CD-18-1212] [Cited by in Crossref: 78] [Cited by in F6Publishing: 100] [Article Influence: 26.0] [Reference Citation Analysis]
556 Awaji M, Singh RK. Cancer-Associated Fibroblasts' Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2019;11:E290. [PMID: 30832219 DOI: 10.3390/cancers11030290] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
557 Salaritabar A, Berindan-neagoe I, Darvish B, Hadjiakhoondi F, Manayi A, Devi KP, Barreca D, Orhan IE, Süntar I, Farooqi AA, Gulei D, Nabavi SF, Sureda A, Daglia M, Dehpour AR, Nabavi SM, Shirooie S. Targeting Hedgehog signaling pathway: Paving the road for cancer therapy. Pharmacological Research 2019;141:466-80. [DOI: 10.1016/j.phrs.2019.01.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
558 Halbrook CJ, Pontious C, Kovalenko I, Lapienyte L, Dreyer S, Lee HJ, Thurston G, Zhang Y, Lazarus J, Sajjakulnukit P, Hong HS, Kremer DM, Nelson BS, Kemp S, Zhang L, Chang D, Biankin A, Shi J, Frankel TL, Crawford HC, Morton JP, Pasca di Magliano M, Lyssiotis CA. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Cell Metab 2019;29:1390-1399.e6. [PMID: 30827862 DOI: 10.1016/j.cmet.2019.02.001] [Cited by in Crossref: 131] [Cited by in F6Publishing: 109] [Article Influence: 43.7] [Reference Citation Analysis]
559 Lei F, Xi X, Batra SK, Bronich TK. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:682-94. [PMID: 30796131 DOI: 10.1124/jpet.118.255786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
560 Pan P, Huang YW, Oshima K, Yearsley M, Zhang J, Arnold M, Yu J, Wang LS. The immunomodulatory potential of natural compounds in tumor-bearing mice and humans. Crit Rev Food Sci Nutr 2019;59:992-1007. [PMID: 30795687 DOI: 10.1080/10408398.2018.1537237] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
561 Girardi D, Barrichello A, Fernandes G, Pereira A. Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives. Cells 2019;8:E153. [PMID: 30759860 DOI: 10.3390/cells8020153] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
562 Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep 2019;9:1788. [PMID: 30742129 DOI: 10.1038/s41598-018-37433-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
563 Simile MM, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu MA, Babudieri S, Madeddu G, Serra PA, Altana M, Paliogiannis P. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina (Kaunas) 2019;55:E42. [PMID: 30743998 DOI: 10.3390/medicina55020042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 8.7] [Reference Citation Analysis]
564 Wang WQ, Liu L, Xu JZ, Yu XJ. Reflections on depletion of tumor stroma in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2019;1871:267-72. [PMID: 30738097 DOI: 10.1016/j.bbcan.2019.01.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
565 Whittle MC, Hingorani SR. Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets. Gastroenterology 2019;156:2085-96. [PMID: 30721663 DOI: 10.1053/j.gastro.2018.12.044] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 12.7] [Reference Citation Analysis]
566 Hu S, Pan L, Shangguan J, Figini M, Eresen A, Sun C, Wang B, Ma Q, Hu C, Yaghmai V, Velichko Y, Yang J, Zhang Z. Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model. Journal of Immunological Methods 2019;465:1-6. [DOI: 10.1016/j.jim.2018.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
567 Raleigh DR, Reiter JF. Misactivation of Hedgehog signaling causes inherited and sporadic cancers. J Clin Invest 2019;129:465-75. [PMID: 30707108 DOI: 10.1172/JCI120850] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
568 Crawford HC, Pasca di Magliano M, Banerjee S. Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. Gastroenterology. 2019;156:2073-2084. [PMID: 30716326 DOI: 10.1053/j.gastro.2018.12.042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
569 Schnittert J, Bansal R, Prakash J. Targeting Pancreatic Stellate Cells in Cancer. Trends Cancer 2019;5:128-42. [PMID: 30755305 DOI: 10.1016/j.trecan.2019.01.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
570 Tanaka HY, Kitahara K, Sasaki N, Nakao N, Sato K, Narita H, Shimoda H, Matsusaki M, Nishihara H, Masamune A, Kano MR. Pancreatic stellate cells derived from human pancreatic cancer demonstrate aberrant SPARC-dependent ECM remodeling in 3D engineered fibrotic tissue of clinically relevant thickness. Biomaterials 2019;192:355-67. [DOI: 10.1016/j.biomaterials.2018.11.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
571 Bastea LI, Liou GY, Pandey V, Fleming AK, von Roemeling CA, Doeppler H, Li Z, Qiu Y, Edenfield B, Copland JA, Tun HW, Storz P. Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. Cancer Res. 2019;79:1535-1548. [PMID: 30696657 DOI: 10.1158/0008-5472.can-18-1153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
572 Tong M, Wang J, Zhang H, Xing H, Wang Y, Fang Y, Pan H, Li D. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials. J Cancer 2019;10:968-78. [PMID: 30854103 DOI: 10.7150/jca.26672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
573 Wang FT, Sun W, Zhang JT, Fan YZ. Cancer-associated fibroblast regulation of tumor neo-angiogenesis as a therapeutic target in cancer. Oncol Lett 2019;17:3055-65. [PMID: 30867734 DOI: 10.3892/ol.2019.9973] [Cited by in Crossref: 17] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
574 Kadel D, Zhang Y, Sun HR, Zhao Y, Dong QZ, Qin LX. Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy. Cell Biol Toxicol 2019;35:407-21. [PMID: 30680600 DOI: 10.1007/s10565-019-09461-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
575 Luo D, Carter KA, Molins EAG, Straubinger NL, Geng J, Shao S, Jusko WJ, Straubinger RM, Lovell JF. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. J Control Release 2019;297:39-47. [PMID: 30684512 DOI: 10.1016/j.jconrel.2019.01.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
576 Liu X, Jiang J, Chan R, Ji Y, Lu J, Liao YP, Okene M, Lin J, Lin P, Chang CH, Wang X, Tang I, Zheng E, Qiu W, Wainberg ZA, Nel AE, Meng H. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer. ACS Nano 2019;13:38-53. [PMID: 30525443 DOI: 10.1021/acsnano.8b06164] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
577 Uzunparmak B, Sahin IH. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med 2019;8:2. [PMID: 30645701 DOI: 10.1186/s40169-019-0221-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
578 Lenggenhager D, Amrutkar M, Sántha P, Aasrum M, Löhr JM, Gladhaug IP, Verbeke CS. Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells. Cells 2019;8:E23. [PMID: 30621293 DOI: 10.3390/cells8010023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
579 Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg 2019;3:130-7. [PMID: 30923782 DOI: 10.1002/ags3.12225] [Cited by in Crossref: 40] [Cited by in F6Publishing: 58] [Article Influence: 13.3] [Reference Citation Analysis]
580 El-zahaby SA, Elnaggar YS, Abdallah OY. Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. Journal of Controlled Release 2019;293:21-35. [DOI: 10.1016/j.jconrel.2018.11.013] [Reference Citation Analysis]
581 Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut 2019;68:159-71. [PMID: 30177543 DOI: 10.1136/gutjnl-2018-316451] [Cited by in Crossref: 149] [Cited by in F6Publishing: 150] [Article Influence: 49.7] [Reference Citation Analysis]
582 Lui JW, Xiao S, Ogomori K, Hammarstedt JE, Little EC, Lang D. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma. J Cancer 2019;10:1-10. [PMID: 30662519 DOI: 10.7150/jca.27472] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
583 Diab M, Azmi A, Mohammad R, Philip PA. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opin Pharmacother 2019;20:535-46. [PMID: 30592647 DOI: 10.1080/14656566.2018.1561869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
584 Cao J, Pickup S, Clendenin C, Blouw B, Choi H, Kang D, Rosen M, O'Dwyer PJ, Zhou R. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2019;25:2314-22. [PMID: 30587546 DOI: 10.1158/1078-0432.CCR-18-2276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
585 Chakrabarti J, Holokai L, Syu L, Steele NG, Chang J, Wang J, Ahmed S, Dlugosz A, Zavros Y. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget 2018;9:37439-57. [PMID: 30647844 DOI: 10.18632/oncotarget.26473] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
586 Swayden M, Iovanna J, Soubeyran P. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Heliyon 2018;4:e01055. [PMID: 30582059 DOI: 10.1016/j.heliyon.2018.e01055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
587 Pietrobono S, Stecca B. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors. Cells 2018;7:E272. [PMID: 30558232 DOI: 10.3390/cells7120272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
588 Ishii N, Araki K, Yokobori T, Hagiwara K, Gantumur D, Yamanaka T, Handa T, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Masamune A, Umezawa K, Kuwano H, Shirabe K. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Cancer Sci 2019;110:334-44. [PMID: 30353606 DOI: 10.1111/cas.13847] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
589 Cortes E, Sarper M, Robinson B, Lachowski D, Chronopoulos A, Thorpe SD, Lee DA, Del Río Hernández AE. GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment. EMBO Rep 2019;20:e46556. [PMID: 30538117 DOI: 10.15252/embr.201846556] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
590 Cortes E, Lachowski D, Robinson B, Sarper M, Teppo JS, Thorpe SD, Lieberthal TJ, Iwamoto K, Lee DA, Okada-Hatakeyama M, Varjosalo MT, Del Río Hernández AE. Tamoxifen mechanically reprograms the tumor microenvironment via HIF-1A and reduces cancer cell survival. EMBO Rep 2019;20:e46557. [PMID: 30538116 DOI: 10.15252/embr.201846557] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
591 Pein M, Oskarsson T. Tamoxifen calms down the distressed PDAC stroma. EMBO Rep 2019;20:e47334. [PMID: 30538119 DOI: 10.15252/embr.201847334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
592 Barati Bagherabad M, Afzaljavan F, ShahidSales S, Hassanian SM, Avan A. Targeted therapies in pancreatic cancer: Promises and failures. J Cell Biochem. 2019;120:2726-2741. [PMID: 28703890 DOI: 10.1002/jcb.26284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
593 Zhang X, Schönrogge M, Eichberg J, Wendt EHU, Kumstel S, Stenzel J, Lindner T, Jaster R, Krause BJ, Vollmar B, Zechner D. Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. Front Oncol 2018;8:590. [PMID: 30568920 DOI: 10.3389/fonc.2018.00590] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
594 Serda M, Ware MJ, Newton JM, Sachdeva S, Krzykawska-Serda M, Nguyen L, Law J, Anderson AO, Curley SA, Wilson LJ, Corr SJ. Development of photoactive Sweet-C60 for pancreatic cancer stellate cell therapy. Nanomedicine (Lond) 2018;13:2981-93. [PMID: 30501557 DOI: 10.2217/nnm-2018-0239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
595 Guo LH, Cao Y, Zhuang RT, Han Y, Li J. Astragaloside IV promotes the proliferation and migration of osteoblast-like cells through the hedgehog signaling pathway. Int J Mol Med 2019;43:830-8. [PMID: 30535481 DOI: 10.3892/ijmm.2018.4013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
596 Freimund AE, Beach JA, Christie EL, Bowtell DD. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. Hematology/Oncology Clinics of North America 2018;32:983-96. [DOI: 10.1016/j.hoc.2018.07.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
597 Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J, Franchimont D, Verset L, Galdon MG, Devière J, de Reyniès A, Laurent-puig P, Van Laethem J, Bachet J, Maréchal R. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology 2018;155:1999-2013.e3. [DOI: 10.1053/j.gastro.2018.08.033] [Cited by in Crossref: 155] [Cited by in F6Publishing: 186] [Article Influence: 38.8] [Reference Citation Analysis]
598 Su X, Ma B, Hu J, Yu T, Zhuang W, Yang L, Li G, Wang Y. Dual-Responsive Doxorubicin-Conjugated Polymeric Micelles with Aggregation-Induced Emission Active Bioimaging and Charge Conversion for Cancer Therapy. Bioconjug Chem 2018;29:4050-61. [PMID: 30404436 DOI: 10.1021/acs.bioconjchem.8b00671] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
599 Bariwal J, Kumar V, Dong Y, Mahato RI. Design of Hedgehog pathway inhibitors for cancer treatment. Med Res Rev 2019;39:1137-204. [PMID: 30484872 DOI: 10.1002/med.21555] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
600 Yeldag G, Rice A, Del Río Hernández A. Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers (Basel) 2018;10:E471. [PMID: 30487436 DOI: 10.3390/cancers10120471] [Cited by in Crossref: 58] [Cited by in F6Publishing: 74] [Article Influence: 14.5] [Reference Citation Analysis]
601 Lagast N, Carlier C, Ceelen WP. Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy. Surg Oncol Clin N Am 2018;27:477-94. [PMID: 29935684 DOI: 10.1016/j.soc.2018.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
602 Zavadil JA, Herzig MCS, Hildreth K, Foroushani A, Boswell W, Walter R, Reddick R, White H, Zare H, Walter CA. C3HeB/FeJ Mice mimic many aspects of gene expression and pathobiological features of human hepatocellular carcinoma. Mol Carcinog 2019;58:309-20. [PMID: 30365185 DOI: 10.1002/mc.22929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
603 Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 2019;18:99-115. [DOI: 10.1038/s41573-018-0004-1] [Cited by in Crossref: 309] [Cited by in F6Publishing: 523] [Article Influence: 77.3] [Reference Citation Analysis]
604 Biffi G, Tuveson DA. Deciphering cancer fibroblasts. J Exp Med 2018;215:2967-8. [PMID: 30470718 DOI: 10.1084/jem.20182069] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
605 Kamposioras K, Tsimplouli C, Verbeke C, Anthoney A, Daoukopoulou A, Papandreou CN, Sakellaridis N, Vassilopoulos G, Potamianos SP, Liakouli V, Migneco G, Del Galdo F, Dimas K. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. Int J Oncol 2019;54:537-49. [PMID: 30483772 DOI: 10.3892/ijo.2018.4640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
606 El-Zahaby SA, Elnaggar YSR, Abdallah OY. Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. J Control Release 2019;293:21-35. [PMID: 30445002 DOI: 10.1016/j.jconrel.2018.11.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
607 Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci 2018;19:E3584. [PMID: 30428588 DOI: 10.3390/ijms19113584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
608 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
609 Vohra R, Park J, Wang YN, Gravelle K, Whang S, Hwang JH, Lee D. Evaluation of pancreatic tumor development in KPC mice using multi-parametric MRI. Cancer Imaging. 2018;18:41. [PMID: 30409175 DOI: 10.1186/s40644-018-0172-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
610 Nielsen MFB, Mortensen MB, Detlefsen S. Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations. World J Gastroenterol 2018; 24(41): 4663-4678 [PMID: 30416314 DOI: 10.3748/wjg.v24.i41.4663] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
611 Elahi-Gedwillo KY, Carlson M, Zettervall J, Provenzano PP. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019;79:372-386. [PMID: 30401713 DOI: 10.1158/0008-5472.can-18-1334] [Cited by in Crossref: 59] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
612 Cuny T, de Herder W, Barlier A, Hofland LJ. Role of the tumor microenvironment in digestive neuroendocrine tumors. Endocr Relat Cancer 2018;25:R519-44. [PMID: 30306777 DOI: 10.1530/ERC-18-0025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
613 Mahajan UM, Langhoff E, Goni E, Costello E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback S, Beyer G, Dombroswki F, Weiss F, Neoptolemos JP, Werner J, D’haese JG, Bazhin A, Peterhansl J, Pichlmeier S, Büchler MW, Kleeff J, Ganeh P, Sendler M, Palmer DH, Kohlmann T, Rad R, Regel I, Lerch MM, Mayerle J. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology 2018;155:1625-1639.e2. [DOI: 10.1053/j.gastro.2018.08.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 95] [Article Influence: 17.3] [Reference Citation Analysis]
614 Jia Y, Gu D, Wan J, Yu B, Zhang X, Chiorean EG, Wang Y, Xie J. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene 2019;38:1764-77. [PMID: 30382189 DOI: 10.1038/s41388-018-0553-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
615 Huang MH, Chou YW, Li MH, Shih TE, Lin SZ, Chuang HM, Chiou TW, Su HL, Harn HJ. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition. Pharmacol Res 2019;139:50-61. [PMID: 30385365 DOI: 10.1016/j.phrs.2018.10.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
616 Gu D, Lin H, Zhang X, Fan Q, Chen S, Shahda S, Liu Y, Sun J, Xie J. Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers (Basel) 2018;10:E403. [PMID: 30373214 DOI: 10.3390/cancers10110403] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
617 Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, Tuveson DA. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov 2019;9:282-301. [PMID: 30366930 DOI: 10.1158/2159-8290.CD-18-0710] [Cited by in Crossref: 269] [Cited by in F6Publishing: 382] [Article Influence: 67.3] [Reference Citation Analysis]
618 Pitarresi JR, Liu X, Avendano A, Thies KA, Sizemore GM, Hammer AM, Hildreth BE 3rd, Wang DJ, Steck SA, Donohue S, Cuitiño MC, Kladney RD, Mace TA, Chang JJ, Ennis CS, Li H, Reeves RH, Blackshaw S, Zhang J, Yu L, Fernandez SA, Frankel WL, Bloomston M, Rosol TJ, Lesinski GB, Konieczny SF, Guttridge DC, Rustgi AK, Leone G, Song JW, Wu J, Ostrowski MC. Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. Life Sci Alliance 2018;1:e201800190. [PMID: 30456390 DOI: 10.26508/lsa.201800190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
619 Cascetta P, Cavaliere A, Piro G, Torroni L, Santoro R, Tortora G, Melisi D, Carbone C. Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. Int J Mol Sci 2018;19:E3331. [PMID: 30366466 DOI: 10.3390/ijms19113331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
620 Zhao J, Xiao Z, Li T, Chen H, Yuan Y, Wang YA, Hsiao CH, Chow DS, Overwijk WW, Li C. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. ACS Nano 2018;12:9881-93. [PMID: 30231203 DOI: 10.1021/acsnano.8b02481] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
621 Vilimas T, Wang AQ, Patnaik S, Hughes EA, Singleton MD, Knotts Z, Li D, Frankowski K, Schlomer JJ, Guerin TM, Springer S, Drennan C, Dextras C, Wang C, Gilbert D, Southall N, Ferrer M, Huang S, Kozlov S, Marugan J, Xu X, Rudloff U. Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemother Pharmacol 2018;82:1067-80. [PMID: 30306263 DOI: 10.1007/s00280-018-3699-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
622 Okumura T, Ohuchida K, Kibe S, Iwamoto C, Ando Y, Takesue S, Nakayama H, Abe T, Endo S, Koikawa K, Sada M, Horioka K, Mochidome N, Arita M, Moriyama T, Nakata K, Miyasaka Y, Ohtsuka T, Mizumoto K, Oda Y, Hashizume M, Nakamura M. Adipose tissue-derived stromal cells are sources of cancer-associated fibroblasts and enhance tumor progression by dense collagen matrix: Adipose tissue-derived stromal cells. Int J Cancer 2019;144:1401-13. [DOI: 10.1002/ijc.31775] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
623 d’Esposito A, Sweeney PW, Ali M, Saleh M, Ramasawmy R, Roberts TA, Agliardi G, Desjardins A, Lythgoe MF, Pedley RB, Shipley R, Walker-samuel S. Computational fluid dynamics with imaging of cleared tissue and of in vivo perfusion predicts drug uptake and treatment responses in tumours. Nat Biomed Eng 2018;2:773-87. [DOI: 10.1038/s41551-018-0306-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
624 Ireland LV, Mielgo A. Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance. Front Cell Dev Biol 2018;6:131. [PMID: 30356656 DOI: 10.3389/fcell.2018.00131] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
625 Ponzoni M, Curnis F, Brignole C, Bruno S, Guarnieri D, Sitia L, Marotta R, Sacchi A, Bauckneht M, Buschiazzo A, Rossi A, Di Paolo D, Perri P, Gori A, Sementa AR, Emionite L, Cilli M, Tamma R, Ribatti D, Pompa PP, Marini C, Sambuceti G, Corti A, Pastorino F. Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles. Small 2018;14:1802886. [DOI: 10.1002/smll.201802886] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
626 Sun Q, Zhang B, Hu Q, Qin Y, Xu W, Liu W, Yu X, Xu J. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics 2018;8:5072-87. [PMID: 30429887 DOI: 10.7150/thno.26546] [Cited by in Crossref: 84] [Cited by in F6Publishing: 100] [Article Influence: 21.0] [Reference Citation Analysis]
627 Zhang Z, Ji S, Zhang B, Liu J, Qin Y, Xu J, Yu X. Role of angiogenesis in pancreatic cancer biology and therapy. Biomed Pharmacother 2018;108:1135-40. [PMID: 30372814 DOI: 10.1016/j.biopha.2018.09.136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
628 Nabavizadeh A, Payen T, Saharkhiz N, McGarry M, Olive KP, Konofagou EE. Technical Note: In vivo Young's modulus mapping of pancreatic ductal adenocarcinoma during HIFU ablation using harmonic motion elastography (HME). Med Phys 2018;45:5244-50. [PMID: 30178474 DOI: 10.1002/mp.13170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
629 Saadat N, Akhtar S, Goja A, Razalli NH, Geamanu A, David D, Shen Y, Gupta SV. Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model. Nutr Cancer 2018;70:1075-87. [PMID: 30273070 DOI: 10.1080/01635581.2018.1502327] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
630 Bisht S, Feldmann G. Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts. Oncol Res Treat 2018;41:596-602. [PMID: 30269126 DOI: 10.1159/000493437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
631 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
632 Lee WK, Lee SG, Yim SH, Kim D, Kim H, Jeong S, Jung SG, Jo YS, Lee J. Whole Exome Sequencing Identifies a Novel Hedgehog-Interacting Protein G516R Mutation in Locally Advanced Papillary Thyroid Cancer. Int J Mol Sci 2018;19:E2867. [PMID: 30241415 DOI: 10.3390/ijms19102867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
633 Chiou SH, Dorsch M, Kusch E, Naranjo S, Kozak MM, Koong AC, Winslow MM, Grüner BM. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 2018;8:14008. [PMID: 30228296 DOI: 10.1038/s41598-018-32159-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
634 Matkar PN, Jong ED, Ariyagunarajah R, Prud'homme GJ, Singh KK, Leong-Poi H. Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer. Cancer Med 2018;7:5036-46. [PMID: 30216699 DOI: 10.1002/cam4.1715] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
635 Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol 2018; 24(33): 3709-3723 [PMID: 30197477 DOI: 10.3748/wjg.v24.i33.3709] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
636 Weniger M, Honselmann KC, Liss AS. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. Cancers (Basel) 2018;10:E316. [PMID: 30200666 DOI: 10.3390/cancers10090316] [Cited by in Crossref: 92] [Cited by in F6Publishing: 110] [Article Influence: 23.0] [Reference Citation Analysis]
637 Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC. Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. Cancer Discov. 2018;8:1458-1473. [PMID: 30185628 DOI: 10.1158/2159-8290.cd-18-0046] [Cited by in Crossref: 64] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
638 Xia G, Zhang H, Cheng R, Wang H, Song Z, Deng L, Huang X, Santos HA, Cui W. Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence. Adv Healthc Mater 2018;7:e1800593. [PMID: 30062854 DOI: 10.1002/adhm.201800593] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
639 Wang P, Wei D, Zhang H, Chen J, Zhang D, Ganapathy S, Isakson P, Chen C, Zhu T. PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis. Oncotarget 2018;9:32736-50. [PMID: 30214681 DOI: 10.18632/oncotarget.25127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
640 Nagathihalli NS, Castellanos JA, Lamichhane P, Messaggio F, Shi C, Dai X, Rai P, Chen X, VanSaun MN, Merchant NB. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Cancer Res 2018;78:6235-46. [PMID: 30154150 DOI: 10.1158/0008-5472.CAN-18-0634] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
641 Bilalis P, Skoulas D, Karatzas A, Marakis J, Stamogiannos A, Tsimblouli C, Sereti E, Stratikos E, Dimas K, Vlassopoulos D, Iatrou H. Self-Healing pH- and Enzyme Stimuli-Responsive Hydrogels for Targeted Delivery of Gemcitabine To Treat Pancreatic Cancer. Biomacromolecules 2018;19:3840-52. [PMID: 30095907 DOI: 10.1021/acs.biomac.8b00959] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
642 Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, Ni QX, Yu XJ, Liu L. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis 2019;22:15-36. [PMID: 30168025 DOI: 10.1007/s10456-018-9645-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 12.5] [Reference Citation Analysis]
643 Qu C, Wang Q, Meng Z, Wang P. Cancer-Associated Fibroblasts in Pancreatic Cancer: Should They Be Deleted or Reeducated? Integr Cancer Ther 2018;17:1016-9. [PMID: 30136592 DOI: 10.1177/1534735418794884] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
644 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
645 Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 2018;17:2377-88. [PMID: 30097486 DOI: 10.1158/1535-7163.MCT-17-1090] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
646 Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? World J Gastroenterol 2018; 24(29): 3222-3238 [PMID: 30090003 DOI: 10.3748/wjg.v24.i29.3222] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
647 Giri B, Sethi V, Dudeja V, Banerjee S, Livingstone A, Saluja A. Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants. Curr Opin Gastroenterol 2017;33:404-10. [PMID: 28682795 DOI: 10.1097/MOG.0000000000000382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 Abel EV, Goto M, Magnuson B, Abraham S, Ramanathan N, Hotaling E, Alaniz AA, Kumar-Sinha C, Dziubinski ML, Urs S, Wang L, Shi J, Waghray M, Ljungman M, Crawford HC, Simeone DM. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife 2018;7:e33947. [PMID: 30074477 DOI: 10.7554/eLife.33947] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
649 Jiang H, Wang S, Zhou X, Wang L, Ye L, Zhou Z, Tang J, Liu X, Teng L, Shen Y. New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. J Control Release 2018;286:254-63. [PMID: 30075209 DOI: 10.1016/j.jconrel.2018.07.047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
650 Erstad DJ, Sojoodi M, Taylor MS, Ghoshal S, Razavi AA, Graham-O'Regan KA, Bardeesy N, Ferrone CR, Lanuti M, Caravan P, Tanabe KK, Fuchs BC. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Dis Model Mech 2018;11:dmm034793. [PMID: 29903803 DOI: 10.1242/dmm.034793] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
651 Qian W, Li J, Chen K, Jiang Z, Cheng L, Zhou C, Yan B, Cao J, Ma Q, Duan W. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sci. 2018;208:253-261. [PMID: 30053447 DOI: 10.1016/j.lfs.2018.07.046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
652 Dugnani E, Pasquale V, Marra P, Liberati D, Canu T, Perani L, De Sanctis F, Ugel S, Invernizzi F, Citro A, Venturini M, Doglioni C, Esposito A, Piemonti L. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Carcinogenesis 2018;39:1197-206. [DOI: 10.1093/carcin/bgy094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
653 Molejon MI, Swayden M, Fanale D, Bintz J, Gayet O, Soubeyran P, Iovanna J. Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. Oncotarget 2018;9:30837-46. [PMID: 30112111 DOI: 10.18632/oncotarget.25745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
654 Aguirre AJ, Collisson EA. Advances in the Genetics and Biology of Pancreatic Cancer. Cancer J 2017;23:315-20. [PMID: 29189326 DOI: 10.1097/PPO.0000000000000286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
655 Whittle MC, Hingorani SR. Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer J 2017;23:326-32. [PMID: 29189328 DOI: 10.1097/PPO.0000000000000289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
656 Dougan SK. The Pancreatic Cancer Microenvironment. Cancer J. 2017;23:321-325. [PMID: 29189327 DOI: 10.1097/ppo.0000000000000288] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 11.5] [Reference Citation Analysis]
657 Carlson M, Watson AL, Anderson L, Largaespada DA, Provenzano PP. Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors. J Biomed Opt 2017;22:1-9. [PMID: 29188660 DOI: 10.1117/1.JBO.22.11.116010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
658 Tanton H, Voronina S, Evans A, Armstrong J, Sutton R, Criddle DN, Haynes L, Schmid MC, Campbell F, Costello E, Tepikin AV. F1F0-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation. Front Physiol 2018;9:833. [PMID: 30050450 DOI: 10.3389/fphys.2018.00833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
659 Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, Moutardier V, Turrini O, Giovannini M, Bian B, Bigonnet M, Rubis M, Elarouci N, Armenoult L, Ayadi M, Duconseil P, Gasmi M, Ouaissi M, Maignan A, Lomberk G, Boher JM, Ewald J, Bories E, Garnier J, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Grandval P, Barraud-Blanc M, Norguet E, Gilabert M, Delpero JR, Roques J, Calvo E, Guillaumond F, Vasseur S, Urrutia R, de Reyniès A, Dusetti N, Iovanna J. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Cell Rep 2017;21:2458-70. [PMID: 29186684 DOI: 10.1016/j.celrep.2017.11.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 19.0] [Reference Citation Analysis]
660 Kumar V, Mundra V, Peng Y, Wang Y, Tan C, Mahato RI. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Theranostics 2018;8:4033-49. [PMID: 30128034 DOI: 10.7150/thno.24945] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
661 Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, Bareja R, Ma Y, Harris EM, Sboner A, Beltran H, Rubin MA, Mukherjee S, Cantley LC. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 2018;560:499-503. [PMID: 30051890 DOI: 10.1038/s41586-018-0343-4] [Cited by in Crossref: 223] [Cited by in F6Publishing: 255] [Article Influence: 55.8] [Reference Citation Analysis]
662 Mohammad AA. Advanced pancreatic cancer: The standard of care and new opportunities. Oncol Rev 2018;12:370. [PMID: 30344961 DOI: 10.4081/oncol.2018.370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
663 Hu G, Zhang Y, Ouyang K, Xie F, Fang H, Yang X, Liu K, Wang Z, Tang X, Liu J, Yang L, Jiang Z, Tao W, Zhou H, Zhang L. In vivo acquired sorafenib-resistant patient-derived tumor model displays alternative angiogenic pathways, multi-drug resistance and chromosome instability. Oncol Lett 2018;16:3439-46. [PMID: 30127946 DOI: 10.3892/ol.2018.9078] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
664 Li X, Shepard HM, Cowell JA, Zhao C, Osgood RJ, Rosengren S, Blouw B, Garrovillo SA, Pagel MD, Whatcott CJ, Han H, Von Hoff DD, Taverna DM, LaBarre MJ, Maneval DC, Thompson CB. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clin Cancer Res 2018;24:4798-807. [PMID: 30084839 DOI: 10.1158/1078-0432.CCR-17-3284] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 7.5] [Reference Citation Analysis]
665 Mohammadi H, Sahai E. Mechanisms and impact of altered tumour mechanics. Nat Cell Biol 2018;20:766-74. [PMID: 29950570 DOI: 10.1038/s41556-018-0131-2] [Cited by in Crossref: 80] [Cited by in F6Publishing: 101] [Article Influence: 20.0] [Reference Citation Analysis]
666 Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Ann Gastroenterol Surg 2018;2:274-81. [PMID: 30003190 DOI: 10.1002/ags3.12176] [Cited by in Crossref: 62] [Cited by in F6Publishing: 86] [Article Influence: 15.5] [Reference Citation Analysis]
667 Ogier C, Colombo PE, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett. 2018;432:227-236. [PMID: 29935372 DOI: 10.1016/j.canlet.2018.06.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
668 Yu X, Kogan S, Chen Y, Tsang AT, Withers T, Lin H, Gilleran J, Buckley B, Moore D, Bertino J, Chan C, Kimball SD, Loh SN, Carpizo DR. Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics. Clin Cancer Res 2018;24:4505-17. [PMID: 29914895 DOI: 10.1158/1078-0432.CCR-18-0822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
669 Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018;8:1096-1111. [PMID: 29903880 DOI: 10.1158/2159-8290.cd-18-0275] [Cited by in Crossref: 113] [Cited by in F6Publishing: 150] [Article Influence: 28.3] [Reference Citation Analysis]
670 Houg DS, Bijlsma MF. The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Mol Cancer. 2018;17:95. [PMID: 29903049 DOI: 10.1186/s12943-018-0842-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
671 Lankadasari MB, Aparna JS, Mohammed S, James S, Aoki K, Binu VS, Nair S, Harikumar KB. Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. Theranostics 2018;8:3824-40. [PMID: 30083262 DOI: 10.7150/thno.25308] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
672 Comen EA, Bowman RL, Kleppe M. Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Front Cell Dev Biol 2018;6:56. [PMID: 29946544 DOI: 10.3389/fcell.2018.00056] [Cited by in Crossref: 24] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
673 Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Mol Cancer Ther 2018;17:1670-82. [PMID: 29891488 DOI: 10.1158/1535-7163.MCT-18-0010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
674 Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E193. [PMID: 29891787 DOI: 10.3390/cancers10060193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
675 Tanaka HY, Kano MR. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci 2018;109:2085-92. [PMID: 29737600 DOI: 10.1111/cas.13630] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
676 Nam GH, Lee EJ, Kim YK, Hong Y, Choi Y, Ryu MJ, Woo J, Cho Y, Ahn DJ, Yang Y, Kwon IC, Park SY, Kim IS. Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer. Nat Commun 2018;9:2165. [PMID: 29867097 DOI: 10.1038/s41467-018-04607-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 53] [Article Influence: 11.0] [Reference Citation Analysis]
677 Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 2018;8:1112-29. [PMID: 29853643 DOI: 10.1158/2159-8290.CD-18-0349] [Cited by in Crossref: 299] [Cited by in F6Publishing: 362] [Article Influence: 74.8] [Reference Citation Analysis]
678 Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncol 2018;14:1409-21. [PMID: 29848096 DOI: 10.2217/fon-2017-0585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
679 Liu J, Zhang Y, Sun S, Zhang G, Jiang K, Sun P, Zhang Y, Yao B, Sui R, Chen Y, Guo X, Tang T, Shi J, Liang H, Piao H. Bufalin Induces Apoptosis and Improves the Sensitivity of Human Glioma Stem-Like Cells to Temozolamide. Oncol Res 2019;27:475-86. [PMID: 29793559 DOI: 10.3727/096504018X15270916676926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
680 Cannon A, Thompson C, Hall BR, Jain M, Kumar S, Batra SK. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes Cancer 2018;9:78-86. [PMID: 30108679 DOI: 10.18632/genesandcancer.171] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
681 Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
682 Haeberle L, Steiger K, Schlitter AM, Safi SA, Knoefel WT, Erkan M, Esposito I. Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. Pancreatology; Epub ahead of print: May 12, 2018. . [PMID: 29778400 DOI: 10.1016/j.pan.2018.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
683 Meng H, Leong W, Leong KW, Chen C, Zhao Y. Walking the line: The fate of nanomaterials at biological barriers. Biomaterials 2018;174:41-53. [PMID: 29778981 DOI: 10.1016/j.biomaterials.2018.04.056] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 17.0] [Reference Citation Analysis]
684 He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y, Chen Q, Ruan C, Guo Q, Li C, Sun T, Jiang C. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Adv Sci (Weinh) 2018;5:1701070. [PMID: 29876225 DOI: 10.1002/advs.201701070] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 13.3] [Reference Citation Analysis]
685 Teichman J, Dodbiba L, Thai H, Fleet A, Morey T, Liu L, McGregor M, Cheng D, Chen Z, Darling G, Brhane Y, Song Y, Espin-Garcia O, Xu W, Girgis H, Schwock J, MacKay H, Bristow R, Ailles L, Liu G. Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma. PLoS One 2018;13:e0194809. [PMID: 29715275 DOI: 10.1371/journal.pone.0194809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
686 Meng H, Nel AE. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Adv Drug Deliv Rev 2018;130:50-7. [PMID: 29958925 DOI: 10.1016/j.addr.2018.06.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
687 Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 2018;130:17-38. [PMID: 30009886 DOI: 10.1016/j.addr.2018.07.007] [Cited by in Crossref: 606] [Cited by in F6Publishing: 522] [Article Influence: 151.5] [Reference Citation Analysis]
688 Drosten M, Guerra C, Barbacid M. Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. Cold Spring Harb Perspect Med 2018;8:a031542. [PMID: 28778964 DOI: 10.1101/cshperspect.a031542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
689 Bali MA, Pullini S, Metens T, Absil J, Chao SL, Marechal R, Matos C, Peerboccus BM, Van Laethem JL. Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. Eur J Radiol. 2018;104:49-57. [PMID: 29857866 DOI: 10.1016/j.ejrad.2018.04.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
690 Birgin E, Hablawetz P, Téoule P, Rückert F, Wilhelm TJ. Chronic pancreatitis and resectable synchronous pancreatic carcinoma: A survival analysis. Pancreatology 2018;18:394-8. [PMID: 29716797 DOI: 10.1016/j.pan.2018.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0]